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Abstract 
 
Some early stage NSCLC patients have a better survival prospects than others. In any 
event, the long-term prognosis for NSCLC patients is poor.  Various measures were 
investigated to gain a better understanding of those patient characteristics that confer 
better survival or predict disease recurrence. A dataset comprised of stage 1 NSCLC 
patients (n=162) that underwent resection was investigated. Clinical variables (CVs) and 
tissue microarray (TMA) images with DNA repair protein and standard H&E expressions 
were investigated. Patients were dichotomized into two groups by survival 
characteristics and logistic regression (LR) modeling was used to predict favorable 
survival outcome. Various patient strata were investigated with Cox regression and 
Kaplan Meier survival analysis (i.e. accepted survival analysis methods). A statistical 
learning (SL) method comprised of a kernel mapping and Differential Evolution 
optimization was developed to integrate SL techniques with LR and accepted survival 
analysis methods by first combining various patient measures to form a hybrid variable.  
Younger age, female gender, and adenocarcinoma subtype confer better survival 
prospects, whereas recurrence confers poor survivability.  The SL hybrid modeling 
produced greater favorable outcome associations and survival hazard relationships than 
the accepted approaches.  Automated texture measures from the HE stained TMA 
images were significantly related to survival, tumor-type, and tumor-grade. DNA repair 
measures in isolation or in combination with CVs were not related to survival, favorable 
outcome or recurrence, and none of the CVs were related to recurrence.  
vi 
 
A platform was established to incorporate automated TMA analysis and SL techniques 
into standard epidemiologic practice, and baseline predictive models were constructed. 
Future work will investigate novel biomarkers and larger datasets using this established 
framework to construct prognostic models for clinical applications for lung cancer 
patients in general and to better understand disease recurrence. 
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Chapter 1: Introduction 
 
Lung cancer is the leading cause of cancer related mortality in the United States as well 
as globally [1-3].  Primarily, there are two types of lung cancer: non-small cell lung 
cancer (NSCLC), which accounts for about 80% of the cases [3], and  small cell lung 
cancer (SCLC), which accounts for about 15% of the cancers [4]. Smoking is the leading 
risk factor for the development of lung cancer, and about 85% of lung cancer deaths are 
attributed to smoking [5].  Non-small cell lung cancer originates from the epithelial cells 
of the lung of the central bronchi to terminal alveoli. The common histological subtypes 
of NSCLC are (a) adenocarcinoma (AC), which represents about 40 % of the cases, (b) 
squamous cell carcinoma (SCC), which accounts for about 39% of the cases, and (c) 
large cell carcinoma, accounting for about 15% of the cases [6]. Although the NSCLC 
subtypes differ in cell size, shape, and chemical makeup, they are categorized as a 
monolithic group because they are treated similarly and have a similar prognosis.   
 
The prognosis for lung cancer patients is generally poor. The five-year survival rate for 
NSCLC patients with stage IV disease is as low as 1% (see Table 1). Improvements in 
therapeutic modalities have resulted in modest improvements in outcome for patients in 
the past two decades. Related work by Behera et al and group shows the efficacy of 
certain treatments for patients with NSCLC in different settings [7-9]. In parallel, we have 
shown that SCLC patients that did not respond to frontline chemotherapy also 
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responded poorly with second-line treatments [10]. Staging of the cancer is significant 
for determining suitable treatment, and patients with early stage cancer can benefit from 
surgical resection [3]. However, a cure remains elusive for patients with advanced stage 
disease and as well as for the majority of stage II and III patients [1, 6].  
 
Lung cancer is often diagnosed at an advanced stage, largely due to the lack of effective 
modalities for early detection [2, 11]. Recent evidence from the National Lung Screening 
Trial shows that low-dose computed tomography (CT) scans can reduce lung cancer 
mortality in comparison with single-view chest radiography when screening high-risk 
patients [6]. Volumetric datasets and high resolution enable helical CT to better detect 
early stage cancers than chest radiography [12, 13]. Before this promising approach is 
incorporated into clinical practice, several important clinical issues must be addressed 
[6, 11].  
 
For patients with early stage lung cancer, local therapy with surgical resection is 
associated with the best survival outcomes. This best case scenario is limited to those 
with NSCLC, which accounts for approximately 85% of all cases of lung cancer in the 
United States.  Despite optimal surgical resection, recurrence of disease is noted in 30-
75 percent of the patients with early stage disease. The development of prognostic 
models for predicting survival outcomes for patients with NSCLC after resection may 
have important healthcare implications [14]. Even in patients with early stage lung 
cancer, there is a critical need to improve cure rates, identify patients at higher risk for 
recurrence, and identify those patients that have better chances of survival.  Previous 
work [2, 15] showed that early stage at diagnosis, younger age, and female gender are 
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favorable prognostic indicators for NSCLC patients. It is also important to note that the 
incidence rates for the various forms of lung cancer appear to be shifting in time [16], 
and that there are both racial and regional differences throughout the United States [17]. 
Both serial and geographical variations in lung-cancer survival patterns indicate that 
survival rates require continual evaluation to ensure the knowledge-base is current.  
 
The survival rates shown in Table 1 were obtained from the National Cancer Institute's 
Surveillance, Epidemiology, and End Results (SEER) database based on people who 
were diagnosed with NSCLC between 1998 and 2000 [18]. These clearly show that early 
stage patients have a survival advantage, but the 5 year survival probability cannot be 
considered favorable.  
Table 1: Five year survival rate across stages 
 
Stage IA IB IIA IIB IIIA IIIB IV 
5- year survival rate 49% 45% 30% 31% 14% 5% 1% 
 
 
Understanding the patient attributes that enhance longer-term survival probability or 
indicate recurrence is necessary to individualize treatment options.  In this work, various 
aspects of stage I NSCLC were investigated. Clinical, pathological, and image 
measures, derived from tissue microarrays (TMAs), were analyzed. The dataset is 
comprised of stage 1 NSCLC patients (n=162) that underwent resection at the WellStar 
Kennestone Hospital, GA, from 2002-2008.   These patients were selected 
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retrospectively and consecutively. This data was collected under an approved protocol 
by the Western Institutional Review Board (WCR20080401; approval # 20081986). This 
work is presented in four parts corresponding to chapters 2-5: 
 
(i) Analyses of survival and recurrence using readily available clinical and 
pathological  data.   
(ii) Study of DNA-repair pathway expression variables. 
(iii) Evaluation of statistical learning (SL) methods for survival analysis. 
(iv)  Automated measurements and analyses of multispectral tissue microarray 
(TMA) image data. 
 
Part i was used to form baseline survival attributes for comparisons using readily 
available variables.  The patient population and measures are described in Part i except 
for the tissue microarray (TMA) data and novel biomarker measures. This population 
sample was used for all of the subsequent investigations discussed in this dissertation. 
In Part ii, experimental biomarkers derived from novel protein stains were used to 
assess whether DNA repair can add to the findings in Part i [14]. Part iii represents an 
exploration to develop and evaluate a method for adapting statistical learning (SL) 
methods for accepted epidemiologic analyses.  In this approach, SL methods were used 
as a pre-processing step to prepare the data for use in logistic regression and survival 
analysis (Cox regression and Kaplan Meier analysis) [19]. This essentially combines the 
strength of SL with these important epidemiologic analysis methods. In Part iv, a system 
was developed to analyze TMA images automatically. TMA images were stained with 
standard techniques and assessed with image processing methods to evaluate whether 
5 
 
there is additional information that is not captured by human observation. Although we 
used low resolution data for this analysis due to technical difficulties, the methods are 
scalable to higher resolution.   
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Chapter 2: Survival Analysis of Stage I Non-Small Cell Lung Cancer 
 
Readily available clinical variables and pathologic features from stage I NSCLC patients 
were analyzed [14]. Two forms of analysis were applied to evaluate the survival 
characteristics of this population. Logistic regression (LR) modeling was used to study 
two groups of patients dichotomized by their survival characteristics to form favorable 
and unfavorable survival outcome groups.  Various models were studied to predict 
favorable outcome. Survival analysis (i.e. Cox regression and Kaplan-Meier analysis) 
was also used to study various patient strata.  The full dataset as well as subsets of data 
dictated by full case ascertainment for the variables under consideration were used for 
this work. The NSCLC patient data described below was used exclusively for this work 
and will not be redefined in subsequent chapters. The evaluation described in this 
chapter was essentially excerpted from the work by Behera et al [14]. 
 
2.1 Study Population and Measures  
The dataset is comprised of patients (n=162) with stage I NSCLC that underwent 
surgical resection at the WellStar Kennestone Hospital, GA, from 2002-2008.   These 
patients were selected retrospectively and consecutively.  The selection criteria included 
all stage I patients that had complete case ascertainment for the variables under 
consideration.  One hundred and one (n1) of these patients were alive at last contact 
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(censored), and 61 (n2) patients died (incident) during the course of the contact interval.  
The clinical and pathological variables abstracted from the patient files included age (i.e. 
age of the patient at the time of surgery) with integer accuracy, gender (binary), smoking 
status (binary), four histological-subtypes [i.e. AC, SCC, LCC, and adenosquamous 
carcinoma (ASC)], tumor-grade, adjuvant treatment, disease recurrence, and tumor-
location within the lung. Stage I was dichotomized as IA and IB subgroups (categorical 
binary variable) as ascertained from the pathology reports.  Past or current smokers (i.e. 
smoking status) were categorized as either a smoker, past or present (yes), or as those 
that never smoked (no). Tumor was graded with a 1-3 integer scale (tumor-grade) 
describing the cancer cell differentiation (a measure of abnormality) derived from 
pathology reports (i.e. grade 1 implies well differentiated cells resembling normal cells  
and grade 3 implies poorly differentiated cells indicating abnormality).   Adjuvant 
treatment was defined as systemic chemotherapy given to the patients after surgical 
removal of the tumor.  Recurrence indicates the relapse of the disease after surgery. 
Tumor-location was defined primarily with four categories: lower lobe, middle lobe, upper 
lobe, and upper/lower lobe. This database (Winship Cancer Institute of Emory University 
Lung Cancer Database) was constructed and managed by the author [20] over the past 
three years (2009-2012) and is still under development. This database is a web-based 
archival management system, designed and developed to store clinical and pathological 
information of lung cancer cases [20]. Data from this system can be exported to SAS 
and MS-Excel. The statistical analysis was performed with the SAS software package 
(SAS Institute, NC) and PASW Statistics 18.0.0 (SPSS Inc).  
 
Two forms of survival analysis were used below. First, the patients were dichotomized 
into two groups based on their survival outcomes. Logistic regression (LR) was used to 
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investigate these two groups using the variables discussed above. Secondly, various 
patient strata were investigated with Cox-regression and Kaplan Meier survival analysis 
The rationale for using two forms of survival analysis is that they provide different 
endpoints (discussed below in the Modeling Strategies Section).  
 
2.2 Analysis Methods  
2.2.1 Favorable Outcome Analysis  
Censored (n1) and incident (n2) patients were used to form favorable and unfavorable 
survival outcome groups, respectively.  The LR modeling was referenced to the 
favorable outcome group (i.e. to predict the probability of a given patient experiencing a 
favorable survival outcome given a specific set of variables). Complete case-
ascertainment for all the variables for the entire patient population was not available. The 
full dataset (full group) and various subgroups of this dataset were studied depending 
upon the case-ascertainment for the variables under investigation. The goal was to find 
those variables related to favorable survival outcome and characterize their association 
strengths. Another aim was to find the collection of variables that provided the greatest 
discrimination (i.e. predictive capability) between these groups. Odds ratios (ORs) were 
used to assess group associations and the area under the receiver operating 
characteristic curve (Az) was used to measure model predictive capability. The ORs are 
cited with 95% confidence intervals (CIs).  In this portion of the analysis, Az was 
computed using standard SAS routine [i.e. assessing the range of (false positive, 
sensitivity) ordered pairs and performing integration with the trapezoid rule]. To avoid 
over fitting and user imposition, interaction terms within the LR model were not 
considered in the favorable outcome modeling. Alternatively, variable interactions were 
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investigated as endpoints below.  The justification for the favorable outcome modeling 
and the dichotomization strategy are discussed in more detail in subsequent sections 
and chapters. Briefly, this form of LR modeling has a different interpretation than the 
time-to-event methods, and the dichotomization technique was necessitated by the 
limited dataset. 
 
2.2.2 Inter-Variable Association Analysis  
Various combinations of variables were used to evaluate possible associations with the 
AC and SCC histology subtypes, gender, and disease recurrence. In this modeling, 
histology, gender, and recurrence were used as the dependent variables for LR.  The LR 
models with the following independent (or input) variables were investigated: age (A), 
tumor-grade (Gr), and gender (G).  The following relationships were investigated to 
predict the two class histology subtypes (i.e. predict SCC): LR(A, Gr), LR(A, G), and 
LR(A, Gr, G). A similar analysis was performed to predict male gender and disease 
recurrence. The independent variables used in the LR model to predict male gender and 
recurrence can be determined from the histology subtype analysis by replacing SCC 
with male gender and disease recurrence, respectively. 
 
 2.2.3 Survival Analysis  
Kaplan-Meier survival probability analysis was applied to evaluate survival differences 
between various patient strata. Hazard ratios (HRs) estimated with Cox regression were 
used to assess group survival characteristics with 95% CIs.  To study age-related 
survival, the patients were dichotomized using the population median age (i.e. 67 years) 
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as the cut-point. The below median age group was used as the reference.  The patient 
population was also dichotomized by two-group histology subtype (i.e. SCC and AC), 
recurrence, adjuvant treatment, and gender; the respective references were AC, no-
recurrence, no-adjuvant treatment, and female gender.   Additionally, stage I subgroups 
were investigated in various strata (i) IA and IB using IA as the reference using the full 
group dataset, (ii) lower age-group patients with stage IA histology as the reference 
compared to the remaining patients in the full group dataset, (iii) all patients with stage 
IA with AC as the reference compared to those remaining patients in the full group, and 
(iv) lower-age group patients with both stage IA and AC as the reference compared to 
remaining patients in the full group. 
 
2.2.4 Modeling Strategies  
These two forms of modeling (i.e. time-to-event and LR favorable outcome analysis) 
convey different information to both the patient and the clinician. Cox regression is not 
typically used to make point estimates at the patient level [21] but can provide an 
instantaneous relative risk given a set of covariates for a given patient. Developing 
methods derived from Cox regression for point estimates is an active field of research 
[21].  Kaplan-Meier analysis is non-parametric and not useful for point estimates. 
Reducing the data resolution to a binary outcome makes the dataset amenable to both 
LR modeling for point estimates specifically and more generally to all forms of binary 
classification applications.  The LR model provides the probability of a pre-defined 
endpoint given a set of specific covariates and thus gives an output that is easily 
interpretable at the patient level.  More generally, converting survival data to a binary 
outcome (i.e. for classification purpose) is an accepted approach in survival prognosis 
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predication [22]. Our approach [14, 19] to survival analysis has a similar prognostic aim 
and it also serves as a simplifying mechanism for accepted time-to-event analysis, as 
demonstrated below. Thus, the dichotomized analysis and the accepted survival 
analysis methods (i.e. Cox regression and Kaplan-Meier analysis) are complementary. 
We also developed a non-standard dichotomization method for the binary modeling.  
Often such dichotomization is based on a pre-defined survival time cut-point [22], not 
incident-censored group status and is discussed in detail below.  
 
2.3 Results  
2.3.1 Patient Characteristics  
Table 2 shows the patient characteristics summarized by combined population, incident 
group, and censored group.  The median age of the patients included in this analysis 
was 67 years. There was a near equal representation of male and females in total. The 
censored patients were younger, more likely to have tumor-grade 1 than those in the 
incident group, whereas the other grades were similar across the groups. The censored 
patients were more likely female and to have AC rather than SCC histology. Although 
only a small number of patients had either ASC or LCC histology-subtypes, those in the 
censored group were more likely to have LCC than those in the incident group. Smoking 
status was similar across the groups, and approximately 20% of the patients were non-
smokers. The incident patients were more likely to have experienced disease recurrence 
and received adjuvant treatment.   Tumor-location (upper lobe, lower lobe, middle lobe, 
upper/lower, upper/middle, lower/middle, chest wall, main stem bronchus) was similar 
across the groups. The censored patients were more likely to have stage IA disease in 
comparison with the incident patients. For the favorable group, the censored time 
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distribution mean and standard deviation (SD) were 3.94 and 1.3 years, respectively.  
For the unfavorable group, the overall survival time distribution mean and SD were 2.19 
and 1.8 years, respectively (not shown in the table). The separation between the group 
means provides the justification for the stratification method.  The incident group patients 
are more likely positive for recurrence, but roughly 64% of these patients are negative 
for recurrence. It also follows that the recurrence status for most of the censored group 
patients is unknown. This suggests that the recurrence variable in this work could be 
qualified more accurately as early recurrence.  
Table 2: Patient characteristics.  This table provides the patient characteristics (Char) for 
the incident group (I), censored group (C), and combined total (Tot). The number of 
samples (n), mean values (Mean), standard deviation (SD) and percentages (%) are 
provided for each characteristic where applicable.  The C and I labels correspond to the 
favorable and unfavorable outcome groups, respectively.  
Char 
I C Tot 
 
N Mean / SD
or % 
N Mean / SD
or %
n Mean / SD
or %
Age 61 69.6 / 7.66 101 65.7 / 8.6 162 67.2 / 8.4 
Tumor-Grade 61 2.23 / 0.62 101 2.10 / 0.69 162 2.15 / 0.66
     One 6 9.84% 19 18.81% 25 15.43% 
     Two 35 57.38% 53 52.48% 88 54.32% 
     Three 20 32.79% 29 28.71% 49 30.25% 
Gender       
     Male 39 63.93% 39 38.61% 78 48.15% 
     Female 22 36.07% 62 61.39% 84 51.85% 
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Table 2 (Continued)       
 
Tumor-type 
      
Adenocarcinoma 30 49.18% 63 62.38% 93 57.41% 
Adenosquamous 2 3.28% 2 1.98% 4 2.47% 
     Large Cell 2 3.28% 11 10.89% 13 8.02% 
     Squamous 26 42.62% 22 21.78% 48 29.63% 
     Unknown 1 1.64% 3 2.97% 4 2.47% 
Smoking       
     Non-Smoker 12 19.67% 19 18.81% 31 19.14% 
     Smoker 47 77.05% 74 73.27% 121 74.69% 
     Unknown 2 3.28% 8 7.92% 10 6.17% 
Recurrence       
     Yes 20 32.79% 6 5.94% 26 16.05% 
     No 39 63.93% 93 92.08% 132 81.48% 
     Unknown 2 3.28% 2 1.98% 4 2.47% 
Tumor-Location       
     Lower Lobe 18 29.51% 26 25.74% 44 27.16% 
     Middle Lobe 5 8.20% 5 4.95% 10 6.17% 
     Upper Lobe 36 59.02% 63 62.38% 99 61.11% 
     Upper/Lower Lobes 0 0.00% 2 1.98% 2 1.23% 
     Upper/Middle Lobes 0 0.00% 1 0.99% 1 0.62% 
     Chest Wall 0 0.00% 1 0.99% 1 0.62% 
     Main Stem Bronchus 0 0.00% 1 0.99% 1 0.62% 
     Unknown 2 3.28% 2 1.98% 4 2.47% 
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Table 2 (Continued)       
Treatment       
Yes 10 16.39% 9 8.91% 19 11.73% 
No 51 83.61% 92 91.09% 143 88.27% 
Stage I       
A 37 60.66% 73 72.28% 110 67.90% 
 B 24 39.34% 28 27.72% 52 32.10% 
 
 
2.3.2 Favorable Outcome Analysis   
For the full group dataset (n=162, with n1=101 and n2 = 61), complete case 
ascertainment for age, gender, adjuvant treatment, tumor-grade, stage I subgroup was 
available. The forward stepwise selection procedure used with LR resulted in a  bivariate 
model. As shown in Table 3, the ORs for age and gender were significant (i.e. the CIs do 
not include unity).  When adjusting for gender, the age association [OR = 0.64 per 
standard deviation (SD) increase] and gender association [OR = 0.39] show increasing 
age and male gender confer an unfavorable survival outcome (i.e. females are 2.6 times 
more likely to be in the favorable group and younger age patients are 1.5 times more 
likely to be in the favorable group). In this age-gender model, Az = 0.683. Adjuvant 
treatment, tumor-grade, and stage I subgroup measures were not significant 
independent predictive factors (i.e. Az < 0.600) and their OR associations were not 
significant. We estimated the standard error (SE) in Az was 0.035.  
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Table 3: Favorable outcome predictions and associations. The full group modeling used 
to predict favorable outcome included: age (A), gender (G), adjuvant treatment (T) noted 
as ‘Treat’ in the covariates (Cov) column, tumor-grade (Gr), stage I subgroup (S1). The 
step-forward selection was used to build a model to predict the censored group (C).  
Only age and gender were significant. The odds ratios (ORs) with 95% confidence 
intervals are provided for each covariate, and the area under the receiver operating 
characteristic curve (Az) is provided for the various arrangements. Non-applicable (NA) 
entries are labeled. The functional notation LR(x,y) was used to indicate the variable(s) 
within the logistic regression (LR) model used to predict the censored group.  
Model Cov Unit / Ref Versus Cov OR Az 
LR(A) =    
censored group Age 8.4 NA 
0.61         
(0.43, 0.87) 0.630 
LR(G) =    
censored group Gender Female Male 
0.36         
(0.18, 0.69) 0.627 
LR(T) =    
censored group Treat No Yes 
0.50         
(  0.19, 1.31) 0.537 
LR(Gr )=   
censored group Grade 1.0 NA 
0.74         
(0.45, 1.20) 0.549 
LR(S1) =  
censored group Stage IA IB 
0.59         
(0.30, 1.16) 0.558 
LR(A,G )= 
censored group 
Age 
Gender
8.4 
Female 
NA 
Male 
0.64         
(0.44, 0.91) 
0.39         
(0.20, 0.75) 
0.683 
 
In the subgroup-1 dataset (n =149, with n1 =91 and n2= 58), patients that had complete 
ascertainment for age, gender, tumor-grade, tumor-location, and histology-subtype were 
included to predict favorable outcome.  This modeling considered all of the measured 
tumor characteristics in combination with age. The univariate analysis found significant 
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associations for age [OR= 0.65 (CI: 0.45, 0.92)] per standard deviation (SD) increase 
and gender [OR=0.32 (CI: 0.16, 0.64)] per unit increase, indicating increasing age and 
male gender confer an unfavorable outcome.  The forward selection process resulted in 
a bivariate model with age and gender, which had similar ORs as the univariate models 
and Az = 0.680. None of the tumor characteristics, including stage I subgroup, 
demonstrated significance (findings not shown).  
 
The subgroup-2 dataset (n= 134 with n1= 80 and n2= 54) was investigated to predict 
favorable outcome by restricting the analysis to patients that had full case ascertainment 
for the SCC and AC histology-subtypes in conjunction with age, gender, tumor-location, 
adjuvant treatment, tumor-grade, and  stage I subgroup. The univariate analysis found 
significant findings for gender [OR = 0.34 (CI: 0.17, 0.70), Az = 0.630] and histology 
subtype [OR= 0.44 (CI: 0.21, 0.91) and Az=0.594]. The forward stepwise procedure 
found the corresponding bivariate model with gender and histology subtype.  In this 
model (i) the ORs were similar to that of the respective univariate models, (ii) the 
combined Az increased to 0.668, and (iii) the OR for histology was not significant. The 
findings show that both AC and female gender confer a favorable survival outcome, and 
these two variables in combination provided an increased Az in comparison with either in 
isolation. The other variables were not significant (data not shown).  It is important to 
note that age was not included in the selection process. The reasons for this were 
investigated below in the interaction analysis.  
 
Different combinations of variables were investigated to determine models with 
increased predictive capability for favorable outcome using the forward stepwise 
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procedure. This subgroup is referred to as the best model dataset (n= 123 with n1=71 
and n2=52). This evaluation included patients with complete case ascertainment for age, 
gender, adjuvant treatment, tumor-grade, stage subgroup, SCC and AC histology-
subtypes, tumor-location, smoking status, and recurrence. The model with the greatest 
predictive capability included gender, histology, and recurrence, which resulted in a 
combined Az of 0.788. In this model the associations for gender [OR = 0.32 (CI: 0.14, 
0.76)], histology subtype [OR = 0.41 (CI: 0.17, 0.98)], and recurrence [OR = 0.04 (CI: 
0.01, 0.20)] were significant and all conferred an unfavorable outcome. The respective 
ORs do not vary much from their respective univariate values (see Table 3) indicating 
they provide independent contributions. Age was then forced into the selected model. 
Although the OR association for age was not significant, its contribution increased the 
model’s predictive capability giving Az = 0.796.  Although recurrence was a strong 
indicator of limited survival, the variable has limited application in general predictive 
modeling in that over 63% of patients in the unfavorable group were negative for 
recurrence as was over 94% of those patients in the censored group (i.e. not known). 
However, understanding the variables related to recurrence is important because given 
recurrence, poor survival is likely.   
 
2.3.3 Interaction Analysis  
To understand possible interactions between age and other variables, inter-
measurement analyses were performed using the subgroup 2 patients. This analysis 
was portioned into three outcomes by considering those variables that could predict (i) 
the two-subgroup histology [i.e. AC or SCC], (ii) gender, and (iii) recurrence. To limit the 
presentation, only models that provided an Az equal to or above 0.600 are shown when 
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the corresponding ORs were not significant. The Az quantities were calculated with SAS 
as described in Section 2.2. The histology relationships are shown in Table 4.  Although 
there are many models that provided some predictive capability, the majority of the OR 
associations were not significant. In all models that contained age, increasing age was 
associated with SCC. The association for age in isolation was [OR = 1.70 (CI: 1.14, 
2.52) per SD increase] with Az = 0.637. The gender associations are shown in Table 5. 
Although tumor-grade in isolation provided weak predictive capability (Az = 0.596), its 
association [OR = 1.84 per unit increase] indicates increasing grade is significantly 
related to male gender; in models that included grade, similar associations were found 
(i.e. 1.46 - 2.01 range of ORs).   To understand possible interactions with disease 
recurrence, several LR models were investigated to predict recurrence.  No significant 
OR relationships or predictors of recurrence were found (data not shown).   
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Table 4: Interaction analysis to predict histology. In this analysis we use the subgroup 
two dataset to predict two class histology: adenocarcinoma (AC) and squamous cell 
carcinoma (SCC). This model included age (A), gender (G), and tumor-grade (Gr). We 
used the functional notation LR(x,y) to indicate the variable(s) within the logistic 
regression model to predict SCC. Odds ratios (ORs) are provided with 95% confidence 
intervals parenthetically. The area under the receiver operating characteristic curve (Az) 
is provided for each model. The unit and reference (ref) and covariate (Cov) ORs are 
also provided for each model. Non-applicable (NA) entries are labeled.   
Model Cov Unit/Ref Versus Cov OR Az 
LR(A)=SCC Age 8.0 NA 
1.70        
(1.14, 2.52) 
0.637 
LR(A, Gr)=SCC 
Age 8.0 NA 
1.76       
 (1.18, 2.65) 
0.651 
Grade 1 NA 
1.43        
(0.79, 2.58) 
LR(A, G)=SCC 
Age 8.0 NA 
1.65      
  (1.11, 2.46) 
0.660 
Gender Female Male 
1.71       
 (0.82, 3.58) 
LR(A, Gr, G)=SCC 
Age 8.0 NA 
1.70         
(1.13, 2.56) 
0.665 Grade 1 NA 
1.32       
 (0.72, 2.42) 
Gender Female Male 
1.58        
(0.74, 3.39) 
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Table 5: Interaction analysis to predict male gender. In this analysis we use the 
subgroup-2 dataset to predict gender.  This model included age (A), tumor-grade (Gr), 
and histology (H), including adenocarcinoma (AC) and squamous cell carcinoma (SCC). 
We use the functional notation LR(x,y) to indicate the variable(s) within the logistic 
regression model  used to predict male gender. Odds ratios (ORs) are provided with 
95% confidence intervals parenthetically.  The area under the receiver operating 
characteristic curve (Az) is provided for each model. The unit, reference (ref) and 
covariate (Cov) ORs are also provided for each model. Non-applicable (NA) entries are 
labeled. 
Model Cov Unit/Ref Vs Cov OR Az 
LR(A)=SCC Age 8.0 NA 1.70            (1.14, 2.52) 0.637
LR(A, Gr)=SCC 
Age 8.0 NA 1.76            (1.18, 2.65) 
0.651
Grade 1 NA 1.43            (0.79, 2.58) 
LR(A, G)=SCC 
Age 8.0 NA 1.65            (1.11, 2.46) 
0.660
Gender Female Male 1.71            (0.82, 3.58) 
LR(A, Gr,G)= 
SCC 
 
Age 8.0 NA 1.70            (1.13, 2.56) 
0.665Grade 1 NA 1.32            (0.72, 2.42) 
Gender Female Male 1.58            (0.74, 3.39) 
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2.3.4 Survival Analysis  
The survival analysis statistical test results, HRs, and survival probabilities are provided 
in Table 6.   Figure 1 shows the dichotomous age grouping survival curves. The upper-
age group is at significantly greater hazard compared with the lower-age group 
[HR=1.86, (CI: 1.11, 3.12)].   This table also provides proportional estimates for those 
surviving past 3, 5, and 7 years.  This shows that 64% of the lower-age group survived 
past five years, whereas 47% of the upper-age group survived past this time. Controlling 
for grade in the age hazard model was not significant [HR=1.93, (CI: 1.11, 3.12)].  Figure 
2 shows the survival curves for patients with SCC compared to patients with AC 
histology subtypes. Patients with SCC are at a significantly increased hazard [HR = 1.78, 
(CI: 1.05, 3.01)].  Over 35% of the patients with AC survived past 7 years, whereas only 
15% of the patients with SCC survived past this time. Controlling for grade with histology 
subtype somewhat confounded the hazard relationship [HR= 1.68, (CI: 0.99, 2. 28)], but 
the change was not significant. The elevated hazard for disease recurrence [HR = 4.16, 
(CI: 2.37,7.31)] significantly limits survival (Figure 3) but note the limited number of 
positive recurrence patients. As shown in Table 6, approximately 38% of the non-
recurrence patients survived past 7 years whereas none of the recurrence patients 
survived past this time.   Although the curves indicate adjuvant treatment limits survival 
(shown in Figure 4), the findings [HR = 1.82, (CI: 0.92, 3.61)] were not significant (i.e. 
considered as a trend).  Figure 5 shows the gender stratified curves indicating males 
have an elevated hazard [HR = 2.03, (CI: 1.20,3.43)] relative to females. However, the 
favorable survival characteristic for females is present mainly for the short and mid-term. 
Past seven years, survival appears similar for both genders (i.e. about 26% males and 
26% of females survived).     
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Figure 1: Age survival. This shows the survival probability curves for the full (full group) 
dataset. The lower-age group (upper blue curve) and upper-age group (lower brown 
curve) were formed by using the median age as the cut-point. The lower-age group has 
a survival advantage [HR = 1.86].  
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Figure 2: Histology subtype survival. This shows the survival probability curves for 
patients with either adenocarcinoma (upper blue curve) or squamous cell carcinoma 
(lower brown curve) histology-types (subgroup-2). The patients with adenocarcinoma 
clearly have a survival advantage [HR=1.7].  
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Figure 3: Disease recurrence survival. This shows survival probability curves for 
patients with disease recurrence (lower blue curve) and without recurrence (upper brown 
curve) for the full group. Disease recurrence limits survival [HR= 4.16]. 
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Figure 4: Adjuvant treatment survival. This shows the survival probability curves 
stratified for patients with treatment (lower blue curve) and without treatment (upper 
brown curve) for the full group. The apparent poorer survival trend for those with 
treatment [HR=1.82] was not significant. 
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Figure 5: Gender survival. This shows the survival curves for males (lower brown curve) 
and females (upper blue curve) for the full group. Males have a significantly elevated 
hazard [HR = 2.03] compared to the females. The survival advantage for females 
appears limited to the short-mid terms.   
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Table 6: Survival analysis associations.  This table provides the hazard ratios (HRs) with 
95% confidence intervals, the Wilcoxon (Wilcox), chi-square (chi-sq), and Log-rank 
(LgR) test p-values (p-val) and the percentage of patients surviving (Sur) past 3, 5, and 7 
years for the various groups.  The number of patients in each stratification belonging to 
the censored group (nc), incident group (nI), and totals (n) for each experiment are also 
provided. We show the survival statistics for age, histology subtype restricted to 
adenocarcinoma (AC) and squamous cell carcinoma (SCC), disease recurrence (Rec), 
adjuvant treatment (treatment), and gender.  The reference (ref) groups are designated 
below. Recurrence and adjuvant treatment are denoted by Rec and treatment 
respectively.  
Model / 
Group 
N 
nI, nC 
Wilcox 
Ch-sq 
( l)
LgR 
Ch-sq 
( l)
HR        
(95% CI) 
3 Year 
% Sur 
5 Year 
% Sur 
7 Year 
% Sur 
Survival 
Age 
162 
61,101 
5.01 
(0.025) 
5.75 
(0.016) 
1.86  
(1.1,3.1)    
Lower-age 
group (ref) 
82 
24, 58    79.1% 64.4% 32.2% 
Upper-age 
group 
80 
37, 43    63.3% 46.7% 29.1% 
Survival 
Histology 
141 
56, 85 
5.08 
(0.024) 
4.68 
(0.030) 
1.78 
(1.1,3.0)    
AC 
(ref) 
93 
30, 63    77.3% 57.6% 35.4% 
SCC 48 26, 22    57.3% 45.5% 15.2% 
Survival 
Rec 
158 
59, 99 
18.28 
(0.000) 
28.79 
(0.000) 
4.16  
(2.4,7.3)    
No Rec 
(ref) 
132 
39, 93    79.6% 65.0% 33.9% 
Rec 26 20, 6    33.7% 11.2% 0.00% 
Survival 
Treatment 
162 
61,101 
1.62 
(0.203) 
3.04 
(0.081) 
1.82 
(0.92,3.6)    
No 
Treatment 
(ref) 
143 
51, 92    72.4% 59.8% 29.6% 
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Table 6 (Continued)       
Treatment 19 
10, 8    63.2% 28.1% 28.1% 
Survival 
Gender 
162 
61,101 
9.39 
(0.002) 
7.27 
(0.007) 
2.03 
(1.20,3.4)    
Female 
(ref) 
84 
22, 62    81.7% 67.6% 
25.80
% 
Male 
 
78 
39, 39    60.2% 44.7% 26.9% 
 
Additional analysis was applied to evaluate various strata based on the stage I 
subgroups (graphs and tables not shown). Stratification by stage IA and IB subgroups 
did not result in a significantly different hazard.  However, stratification by considering all 
patients in the lower-age group with stage IA compared to the remaining population was 
associated with a significant hazard [HR = 2.44, (CI: 1.30, 4.59)], indicating that older 
age in combination with stage IB confers poor survival relative to the remaining stage I 
population.   Similarly, stratification by considering patients with both AC and Stage IA 
compared to the remaining population resulted in a significant hazard [HR = 2.18, (CI: 
1.22, 3.88)].  Stratification by considering patients with AC, stage IA and in the lower-age 
group compared with the remaining population was associated with a significant hazard 
[HR= 2.65, (CI: 1.20, 5.84)]. Thus, stage subgroup was related to survival when 
considering those patients with specific clinical factors. 
 
As previously demonstrated [19], the work also shows that the LR analysis based on the 
incident and censored group for favorable outcome predictions provided a means for 
determining those variables related to survival as evaluated with accepted analysis 
methods (i.e. Cox regression and Kaplan Meier analysis).  
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The analysis methods presented in this chapter were repeated using measures of DNA 
repair protein expression in the tumor tissues of the patients from this dataset presented 
in the next chapter. 
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Chapter 3: Analysis of DNA Repair Pathway Expression in Stage I NSCLC 
 
Both clinical and molecular characteristics of tumors can be used to determine 
prognosis. In particular, the expression of excision repair cross complementing gene 1 
(ERCC1) was shown as a  prognostic factor in patients with early stage NSCLC [23]. 
ERCC1 plays an important role in the nucleotide excision repair pathway. Given that 
DNA repair is mediated by a number of other important pathways as well, the impact of 
PARP and Ku86 expression was investigated along with clinical factors [2, 15] to identify 
the variables that either limit survival or confer survivability [24, 25]. Ku86 and PARP are 
involved in the non-homologous end joining and base excision repair pathways 
respectively. It was hypothesized that the expression of each of these proteins could 
influence prognosis and treatment selection for patients with NSCLC.  We also 
hypothesized that these expression measures may be related to disease recurrence.  
 
3.1 Experimental Protein Expression Biomarker Measures 
DNA repair protein expression for Ku86 and PARP were evaluated as disease 
biomarkers from digitally scanned, immunohistochemically stained NSCLC tissue 
microarrays (TMA).  A board certified pathologist reviewed selected hematoxlyin and 
eosin (H&E) stained slides to confirm the diagnosis and grade of the tumors.  
Subsequently, areas of interest were identified on the H&E stained slides and tissue
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cores were obtained from the corresponding areas of the originating formalin fixed 
paraffin embedded tissue block using a semi-automated tissue microarrayer (Pathology 
Devices, Westminster, MD).  Due to the inherent histological heterogeneity of non small 
cell lung carcinomas, especially adenocarcinomas, triplicate tumor tissue cores were 
obtained to account for tumor heterogeneity.  Immunohistochemical staining of the 4 µm 
thick sections from the TMA blocks was performed using monoclonal antibodies to 
Ku86(SC- 56136 Santa Cruz) and PARP (Cat # 630210; Clontech) according to the 
manufacturer’s instructions for immunhistochemical staining using an automated stainer 
(Dako, Carpinteria, CA). The immunohistochemically stained TMA slides were digitized 
using a Nanozoomer© whole slide scanner (Olympus, Center Valley, PA).  Protein 
expression was evaluated from digitized, stained TMA pathology images using a 
modified scoring methodology.  The stain intensity was assessed for each tissue core 
manually by the pathologist. A final intensity score for each patient was determined by 
averaging the scores of the 3 tumor cores of a sample. This method of scoring was 
repeated for every patient. The three measures were derived for each DNA repair 
protein expression that measured intensity (I), proportion (P) and total score (S)  [i.e. 
intensity × proportion]. For Ku86, we refer to these as KI, KP, and KS, respectively. 
Similarly, the corresponding PARP measures were referred to as  PI, PP, and PS 
respectively.  
 
Due to the proprietary nature of the novel methodology described above, these TMA 
images were not available or accessible for automated analysis. Only the manual 
scoring data derived from the pathologist was available for the work presented in this 
chapter.  
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3.2 Study Population and Methods of Analysis 
This data corresponds to the NSCCLC patients and data described in the previous 
chapter.  Please refer to Chapter 2, section 2.1 for the description of study population 
and section 2.2 for analysis methods.  Favorable outcomes were modeled in a similar 
fashion. Variable interactions were also investigated.   In this modeling, histology (either 
AC or SCC), gender, and recurrence were used as the dependent variables for the LR 
model (as demonstrated in Chapter 2). The LR models included the following variables: 
age (A), tumor-grade (Gr), gender (G) and the protein expression measures.   Each of 
these clinical and pathological variables are generically referred to as CL1, and each of 
the six DNA repair protein expression variables are generically referred to as PR in this 
description.  The following relationships were investigated to predict the two class 
histology subtypes (i.e. predict SCC): LR(CL1, PR), LR(A, Gr, PR), LR(A, G, PR), and 
LR (A, Gr, G, PR). This evaluation included 56 different LR models. We performed a 
similar analysis to predict male gender. The independent variables used in the LR model 
to predict male gender can be determined from the histology (H) subtype analysis by 
replacing G with H (i.e. 56 different LR models).   Various relationships were used to 
predict recurrence. We refer to A, Gr, H, and G individually as the CL2 variables in this 
description. We investigated, LR(CL2), LR(PR), LR(CL2, PR), LR(A, Gr), LR(A, H), 
LR(A, G), LR(CL2, PR), LR(A, Gr, H), LR(A, Gr, G), LR(A, H, G), LR(A, Gr, PR), LR(A, 
H, PR), LR(A,G, PR). LR(Gr, H, PR), LR(Gr, G, PR), LR(H, G, PR), LR(A, Gr, H, PR), 
LR(A, H, G, PR), LR(Gr, H, G, PR), LR(A, Gr, H, G, PR). This evaluation included 110 
LR models. The models were formed manually (without automated selection). For the 
survival analysis using DNA repair expression measures, similar methods were followed, 
as described in Chapter 2, section 2.2. 
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3.3 Results 
3.3.1 Favorable Outcome Analysis 
The additional patient characteristics for biomarker groups are summarized in Table 7 by 
incident and censored group. The Ku86 and PARP expression for each of the three 
measures were similar across the two groups. In the modeling and survival analyses 
below, KI findings were excluded because all males had KI =3, as did most females 
(majority of patients had the same value).  
Table 7: Patient characteristics for biomarker groups. This table provides the patient 
characteristics for the incident group (I), censored group (C), and total (Tot) for the 
biomarkers. The number of samples (n), mean values (Mean), standard deviation (SD) 
and percentages (%) are provided for each characteristic where applicable.  The C and I 
labels correspond to the favorable and unfavorable outcome groups, respectively. 
 
Biomarker 
I 
 
C        Tot    
n Mean / SD 
or % 
n Mean / SD 
or % 
n Mean / SD  
or % 
KP 61 96.9 / 6.6 101 97.1 / 4.0 162 97.1 / 5.1 
KS 61 289.5 /24.8 101 288./ 21.5 162 288.7 / 22.7 
PI 61 2.58 / 0.60 101 2.51 / 0.62 162 2.54 / 0.61 
PP 61 83.6 / 17.5 101 84.9 / 18.2 162 84.4 /17.9 
PS 61 223.4/ 76.9 101 221.6 /77.4 162 222.8 / 76.7 
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For the full group dataset (n=162, with n1=101 and n2 = 61), the DNA repair protein 
expression measures were not significant independent predictive factors for favorable 
outcome (i.e. Az < 0.600) and their OR associations were not significant as shown in 
Table 8.  
 
Table 8: DNA repair associations for the full group dataset.  The odds ratios (ORs) with 
95% confidence intervals, and area under the receiver operating characteristic curve 
(Az) are provided for the various arrangements. We use the functional notation LR(x,y) 
to indicate the variable(s) within the logistic regression (LR) model used to predict the 
censored group. The unit and reference (ref) and covariate (Cov) ORs are also provided 
for each model.  
Model Cov Unit/Ref Cov OR Az 
LR(KP)=censored 
group KP 5.121 
1.03 
(0.75, 1.41) 
0.479 
LR(KS)=censored 
group KS 22.753 
0.95 
(0.68, 1.32) 
0.530 
LR(PI)=censored 
group PI 0.612 
0.90 
(0.65, 1.25) 
0.527 
LR(PP)=censored 
group PP 17.896 
1.08 
(0.79, 1.47) 
0.540 
LR(PS)=censored 
group PS 76.711 
0.98 
(0.71, 1.34) 
0.498 
 
In the subgroup-1 dataset (n =149, with n1 =91 and n2= 58), patients that had complete 
ascertainment for age, gender, tumor-grade, tumor-location, histology-subtype, and DNA 
repair protein expression measures were included. None of DNA repair protein 
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expression measures demonstrated significant association with favorable outcome (data 
not shown). 
 
The subgroup-2 dataset (n= 134 with n1= 80 and n2= 54) was investigated by restricting 
the analysis to patients that had full case ascertainment for the SCC and AC histology-
subtypes in conjunction with age, gender, tumor-location, adjuvant treatment, tumor-
grade, stage I subgroup, and DNA repair protein expression measures. None of the DNA 
expression measures demonstrated significant association with favorable outcome or 
significantly altered the associations found previously in Chapter 2 when modeled 
simultaneously with the respective covariates (associations not shown). 
 
3.3.2 Interaction Analysis  
To understand possible interactions between age and the DNA repair protein expression 
measures, inter-measurement analyses were performed using the subgroup-2 patients. 
This analysis was portioned into three outcomes by considering those variables that 
could predict (i) the two-subgroup histology [i.e. AC or SCC], (ii) gender, and (iii) 
recurrence. To limit the presentation, only models that were associated with Az equal to 
or above 0.600 are shown when the corresponding ORs were not significant. 
 
In the LR histology association analysis, there were many models that provided some 
predictive capability, whereas, the majority of the OR associations were not significant 
as show in Table 9.  The associations for the PARP and Ku86 expression measures 
were not significant, although the gender association [OR = 2.17] gained significance in 
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the LR(Gr, G, KS) model indicating males are more likely to have the SCC histology 
subtype than females.   
 
In the LR models for gender interaction analyses (Table 10), the majority of the 
associations were not significant except for those provided by tumor-grade and Ku86 
expression. Although grade in isolation provided weak predictive capability (Az=0.596), 
its association [OR = 1.84 per unit increase] indicates increasing grade is significantly 
related to male gender; in models that included grade, similar associations were found 
(i.e. 1.46 - 2.01 range of ORs).   Similarly, KS in isolation provided a significant 
association [OR = 2.03 per SD increase] with Az = 0.635, indicating a relationship with 
gender (i.e. increasing KS is related to male gender). In most models that included KS, it 
provided significant associations (i.e. 1.84 - 2.14 range of ORs).  Histology gained 
significance when including KS.  In this bivariate model the associations for histology 
subtype, [OR=2.14] and KS [OR = 2.05 per SD increase] with the Az = 0.681, show 
males are more likely to have SCC and an increased KS measure.  
 
To understand possible interactions with disease recurrence, several (i.e. 110) LR 
models were investigated. We found only weak predictors of recurrence with no 
significant OR relationships. For example in summary, no univariate model was 
associated with an Az greater than 0.582 (provided by tumor-grade), no bivariate model 
had an Az greater than 0.619 (grade and PI), no trivariate model had an Az greater than 
0.625 (grade, gender, PI), and no models with four variates resulted in an Az as large as 
the best trivariate model (data not shown).    
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Table 9: Histology association analysis.   In this analysis we use the subgroup-2 dataset 
to predict two class histology: adenocarcinoma (AC) and squamous cell carcinoma 
(SCC). This model included age (A), gender (G), Adjuvant treatment  (T) tumor-grade 
(Gr), stage I subgroup  (S1), and  tumor-location (Loc), and DNA expression measures.  
We use the functional notation LR(x,y) to indicate the variable(s) within the logistic 
regression model  used to predict SCC. The unit and reference (ref) and covariate (Cov) 
ORs are also provided for each model with 95% confidence intervals (CIs).  
Model Cov Unit/RefS Versus Cov OR Az 
LR(A, PI)=SCC 
Age 7.967 NA 1.75 (1.17, 2.62) 
0.652
PI 0.605 NA 0.82 (0.57, 1.18) 
LR(A, PP)=SCC 
Age 7.967 NA 1.70 (0.14, 2.53) 
0.637
PP 18.082 NA 0.98 (0.68, 1.42) 
LR(A, PS)=SCC 
Age 7.967 NA 1.74 (1.17, 2.60) 
0.643
PS 75.787 NA 0.87 (0.60, 1.25) 
LR(A, KP)=SCC 
Age 7.967 NA 1.70 (1.15, 2.52) 
0.639
KP 3.601 NA 0.97 (0.67, 1.40) 
LR(A, KS)=SCC 
Age 7.967 NA 1.73 (1.16, 2.58) 
0.652
KS 19.677 NA 0.75 (0.51, 1.12) 
LR(G, PI)=SCC 
Gender Female Male 1.99 (0.96, 4.14) 
0.605
PI 0.605 NA 0.85 (0.59, 1.21) 
LR(G, PS)=SCC 
Gender Female Male 1.95 (0.94, 4.03) 
0.604
PS 75.787 NA 0.91 (0.63, 1.30) 
LR(G, KP)=SCC 
Gender Female Male 1.93 (0.93, 4.02) 
0.604
KP 3.601 NA 0.95 (0.66, 1.37) 
LR(G, KS)=SCC 
Gender Female Male 2.24 (1.05, 4.77) 
0.623
KS 19.677 NA 0.72 (0.50, 1.05) 
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Table 9 (Continued)      
LR(A, Gr, PI)=SCC 
Age 7.967 NA 1.82 (1.20, 2.76) 
0.660Grade 1 NA 1.42 (0.79, 2.58) 
PI 0.605 NA 0.82 (0.57, 1.18) 
 
LR(A, Gr, PP)=SCC 
Age 7.967 NA 1.77 (0.18, 2.67) 
 
0.653Grade 1 NA 1.44 (0.79, 2.60) 
PP 18.082 NA 0.96 (0.66, 1.39) 
 
LR(A, Gr, PS)=SCC 
Age 7.967 NA 1.82 (1.20, 2.75) 
 
0.660Grade 1 NA 1.44 (0.79, 2.61) 
PS 75.787 NA 0.86 (0.60, 1.24) 
 
LR(A, Gr, KP)=SCC 
Age 7.967 NA 1.77 (1.18, 2.66) 
 
0.651Grade 1 NA 1.44 (0.79, 2.60) 
KP 3.601 NA 0.96 (0.66, 1.38) 
LR(A, Gr, KS)=SCC 
Age 7.967 NA 1.82 (1.20, 2.75) 
0.667Grade 1 NA 1.50 (0.82, 2.74) 
KS 19.677 NA 0.73 (0.49, 1.10) 
LR(A, G, PI)=SCC 
Age 7.967 NA 1.70 (1.13, 2.56) 
0.680Gender Female Male 1.80 (0.85, 3.81) 
PI 0.605 NA 0.80 (0.55, 1.15) 
LR(A, G, PP)=SCC 
Age 7.967 NA 1.65 (1.11, 2.47) 
0.662Gender Female Male 1.71 (0.82, 3.59) 
PP 18.082 NA 0.97 (0.67, 1.41) 
LR(A, G, PS)=SCC 
Age    7.967 NA 1.70 (1.13, 2.55) 
0.670Gender Female Male 1.77 (0.84, 3.73) 
PS 75.787 NA 0.84 (0.58, 1.22) 
 
LR(A, G, KP)=SCC 
Age 7.967 NA 1.66 (1.11, 2.47) 
 
0.665Gender Female Male 1.75 (0.93, 3.72) 
KP 3.601 NA 0.93 (0.64, 1.35) 
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Table 9 (Continued)      
 
LR(A, G, KS)=SCC 
Age 7.967 NA 1.68 (1.12, 2.53) 
 
0.681Gender Female Male 2.04 (0.94, 4.43) 
KS 19.677 NA 0.69 (0.45, 1.05) 
LR(Gr, G, PI)=SCC 
Grade 1 NA 1.14 (0.64, 2.02) 
0.604Gender Female Male 1.93 (0.92, 4.07) 
PI 0.605 NA 0.85 (0.59, 1.22) 
LR(Gr, G, KS)=SCC 
Grade 1 NA 1.17 (0.65, 2.10) 
0.624Gender Female Male 2.17 (1.01, 4.66) 
KS 19.677 NA 0.72 (0.49, 1.05) 
LR(A, Gr, G,PI)=SCC 
Age 7.967 NA 1.75 (1.16, 2.66) 
0.678
Grade 1 NA 1.30 (0.70, 2.40) 
Gender Female Male 1.67 (0.77, 3.61) 
PI 0.605 NA 0.80 (0.56, 1.16) 
 
LR(A,Gr,G,PP)=SCC 
Age 7.967 NA 1.71 (1.13, 2.59) 
 
0.666
Grade 1 NA 1.32 (0.72, 2.45) 
Gender Female Male 1.59 (0.74, 3.39) 
PP 18.082 NA 0.96 (0.66, 1.39) 
LR(A,Gr,G, PS)=SCC 
Age 7.967 NA 1.75 (1.15, 2.66) 
 
0.672
Grade 1 NA 1.32 (0.72, 2.44) 
Gender Female Male 1.64 (0.76, 3.52) 
PS 75.787 NA 0.84 (0.58, 1.22) 
LR(A,Gr,G, KP)=SCC 
Age 7.967 NA 1.71 (1.13, 2.58) 
0.665
Grade 1 NA 1.33 (0.72, 2.44) 
Gender Female Male 1.63 (0.75, 3.52) 
KP 3.601 NA 0.92 (0.63, 1.34) 
LR(A,Gr,G, KS)=SCC 
Age 7.967 NA 1.75 (1.15, 2.66) 
0.683
Grade 1 NA 1.36 (0.73, 2.53) 
Gender Female Male 1.89 (0.85, 4.16) 
KS 19.677 NA 0.68 (0.45, 1.04) 
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Table 10: Gender association analysis. In this analysis we use the subgroup-2 dataset 
to predict gender.  This model included age (A), Adjuvant treatment  (T) tumor-grade 
(Gr),  histology (H) including adenocarcinoma (AC) and squamous cell carcinoma 
(SCC), stage I subgroup  (S1), tumor-location (Loc), and the DNA expression measures. 
We use the functional notation LR(x,y) to indicate the variable(s) within the logistic 
regression model  used to predict male gender. The unit and reference (ref) and 
covariate (Cov) ORs are also provided for each model. 
Model Cov Unit/Ref Versus Cov OR Az 
LR(KP)=MALE KP 3.601 NA 1.46 (0.98, 2.17) 0.625
LR(KS)=MALE KS 19.677 NA 2.03 (1.08, 3.82) 0.635
LR(A, PI)=MALE 
Age 7.967 NA 1.32 (0.93, 1.88) 
0.607
PI 0.605 NA 1.26 (0.89, 1.80) 
LR(A, PP)=MALE 
Age 7.967 NA 1.35 (0.95, 1.92) 
0.585
PP 18.082 NA 1.08 (0.76, 1.52) 
LR(A, PS)=MALE 
Age 7.967 NA 1.32 (0.93, 1.88)  
0.600PS 75.787 NA 1.22 (0.86, 1.73) 
LR(A, KP)=MALE 
Age 7.967 NA 1.33 (0.93, 1.91) 
0.654
KP 3.601 NA 1.43 (0.96, 2.11) 
LR(A, KS)=MALE 
Age 7.967 NA 1.33 (0.93, 1.92) 
0.666
KS 19.677 NA 1.96 (1.05, 3.65) 
LR(Gr, PI)=MALE 
Grade 1 NA 1.88 (1.07, 3.29) 
0.623
PI 0.605 NA 1.34 (0.94, 1.91) 
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Table 10 (Continued)      
LR(Gr, PP)=MALE 
Grade 1 NA 1.82 (1.05, 3.17) 
0.584
PP 18.082 NA 1.08 (0.76, 1.52) 
LR(Gr, PS)=MALE 
Grade 1 NA 1.84 (1.06, 3.21) 
0.624
PS 75.787 NA 1.27 (0.89, 1.81) 
LR(Gr, KP)=MALE 
Grade 1 NA 1.80 (1.03, 3.14) 
0.646
KP 3.601 NA 1.43 (0.97, 2.10) 
LR(Gr, KS)=MALE 
Grade 1 NA 1.75 (1.00, 3.07) 
0.655
KS 19.677 NA 1.94 (1.05, 3.60) 
LR(H, PI)=MALE 
Histology AC SCC 2.00 (0.96, 4.15) 
0.607
PI 0.605 NA 1.34 (0.94, 1.92) 
LR(H, PP)=MALE 
Histology AC SCC 1.90 (0.92, 3.90) 
0.573
PP 18.082 NA 1.10 (0.78, 1.56) 
LR(H, PS)=MALE 
Histology AC SCC 1.95 (0.94, 4.03) 
0.610
PS 75.787 NA 1.29 (0.91, 1.83) 
LR(H, KP)=MALE 
Histology AC SCC 1.93 (0.93, 4.01) 
0.660
KP 3.601 NA 1.47 (0.98, 2.19) 
LR(H, KS)=MALE 
Histology AC SCC 2.14 (1.01, 4.55) 
0.681
KS 19.677 NA 2.05 (1.10, 3.80) 
LR(A, Gr, PI)=MALE 
Age 7.967 NA 1.41 (0.97, 2.05) 
0.655Grade 1 NA 2.04 (1.14, 3.64) 
PI 0.605 NA 1.28 (0.89, 1.84) 
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Table 10 (Continued)      
LR(A, Gr, PP)=MALE 
Age 7.967 NA 1.45 (1.00, 2.10) 
0.652Grade 1 NA 2.00 (1.13, 3.56) 
PP 18.082 NA 1.04 (0.73, 1.48) 
LR(A, Gr, PS)=MALE 
Age 7.967 NA 1.42 (0.98, 2.05) 
0.652Grade 1 NA 2.00 (1.13, 3.56) 
PS 75.787 NA 1.21 (0.85, 1.73) 
LR(A, Gr, KP)=MALE 
Age 7.967 NA 1.43 (0.98, 2.07) 
0.685Grade 1 NA 1.96 (1.10, 3.49) 
KP 3.601 NA 1.38 (0.94, 2.02) 
LR(A, Gr, KS)=MALE 
Age 7.967 NA 1.42 (0.98, 2.07) 
0.696Grade 1 NA 1.90 (1.07, 3.39) 
KS 19.677 NA 1.84 (1.01, 3.35) 
LR(A, H, PI)=MALE 
Age 7.967 NA 1.24 (0.86, 1.78) 
 
0.634
Histology AC SCC 1.80 (0.85, 3.83) 
PI 0.605 NA 1.30 (0.91, 1.87) 
LR(A, H, PP)=MALE 
Age 7.967 NA 1.28 (0.89, 1.83) 
0.621Histology AC SCC 1.70 (0.81, 3.57) 
PP 18.082 NA 1.08 (0.76, 1.53) 
LR(A, H, PS)=MALE 
Age 7.967 NA 1.24 (0.86, 1.79) 
 
0.627
Histology AC SCC 1.76 (0.83, 3.72) 
PS 75.787 NA 1.25 (0.87, 1.78) 
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Table 10 (Continued)      
LR(A, H, KP)=MALE 
Age 7.967 NA 1.26 (0.87, 1.82) 
0.681Histology AC SCC 1.74 (0.82, 3.69) 
KP 3.601 NA 1.44 (0.97, 2.14) 
LR(A, H, KS)=MALE 
Age 7.967 NA 1.24 (0.85, 1.81) 
0.698Histology AC SCC 1.94 (0.89, 4.20) 
KS 19.677 NA 1.99 (1.07, 3.68) 
LR(Gr, H, PI)=MALE 
Grade 1 n/a 1.85 (1.05, 3.26) 
0.643Histology AC SCC 1.94 (0.92, 4.08) 
PI 0.605 NA 1.37 (0.95, 1.97) 
LR(Gr, H, PP)=MALE 
Grade 1 NA 1.79 (1.02, 3.13) 
0.620Histology AC SCC 1.84 (0.88, 3.82) 
PP 18.082 NA 1.08 (0.76, 1.53) 
LR(Gr, H, PS)=MALE 
Grade 1 NA 1.81 (1.03, 3.18) 
0.641Histology AC SCC 1.89 (0.90, 3.96) 
PS 75.787 NA 1.29 (0.90, 1.85) 
 
LR(Gr, H, KP)=MALE 
Grade 1 NA 1.76 (1.00, 3.10) 
 
0.676
Histology AC SCC 1.87 (0.89, 3.92) 
KP 3.601 NA 1.43 (0.97, 2.12) 
LR(Gr, H, KS)=MALE 
Grade 1 NA 1.71 (0.97, 3.01) 
0.695Histology AC SCC 2.07 (0.96, 4.43) 
KS 19.677 NA 1.95 (1.07, 3.56) 
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Table 10 (Continued)      
LR(A,Gr, H,PI)=MALE 
Age 7.967 NA 1.33 (0.91, 1.95) 
 
0.667
Grade 1 NA 1.99 (1.11, 3.57) 
Histology AC SCC 1.69 (0.79, 3.65) 
PI 0.605 NA 1.32 (0.91, 1.90) 
 
LR(A,Gr,H,PP)=MALE 
Age 7.967 NA 1.38 (0.95, 2.02)  
 
0.666
Grade 1 NA 1.95 (1.09, 3.49) 
Histology AC SCC 1.59 (0.75, 3.39) 
PP 18.082 NA 1.05 (0.73, 1.49) 
LR(A,Gr,H,PS)=MALE 
Age 7.9679 NA 1.34 (0.91, 1.96) 
0.662
Grade 1 NA 1.95 (1.09, 3.49) 
Histology AC SCC 1.65 (0.77, 3.54) 
PS 75.787 NA 1.24 (0.86, 1.78) 
LR(A,Gr,H,KP)=MALE 
Age 7.967 NA 1.35 (0.92, 1.99) 
0.703
Grade 1 NA 1.91 (1.06, 3.42) 
Histology AC SCC 1.63 (0.76, 3.51) 
KP 3.601 NA 1.39 (0.95, 2.05) 
LR(A,Gr,H,KS)=MALE 
Age 7.967 NA 1.33 (0.90, 1.97) 
0.717
Grade 1 NA 1.84 (1.02, 3.30) 
Histology AC SCC 1.81 (0.82, 3.97) 
KS 19.677 NA 1.86 (1.03, 3.36) 
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In summary, the favorable outcome modeling produced little when using these novel 
DNA repair markers.   
 
3.3.3 Survival Analysis 
The DNA repair protein expression survival findings are shown in Table 11. None of 
these measures showed significance. The PI measure showed the strongest trend [HR = 
1.49]. Approximately 64% of the patients in the lower PI group survived past 5 years, 
whereas 45% of the patients in the upper PI group survived past this time. These 
findings (i.e. no relationship to hazard) reinforce the principle discussed earlier that the 
favorable outcome findings parallel the survival analysis findings for a given variable.  
 
Table 11: DNA repair expression measures and survival.  This table provides the hazard 
ratios (HRs) with 95% confidence intervals, the Wilcoxon (Wil), Chi-square (Chi-sq), and 
Log-rank (LgR) test p-values and the percentage of patients surviving (Sur) past 3, 5, 
and 7 years for the various DNA expression measures.  Patients were dichotomized by 
their respective expression distribution median values (i.e described as low and high).  
The number of patients in each stratification belonging to the censored group (nc), 
incident group (nI) and totals (n) for each experiment are also provided.  
Model / 
Group 
   N 
(nI, nC) 
Wil 
Chi-Sq 
(p-val) 
LgR  
Chi-Sq 
(p-val) 
HR        
(95% CI) 
3 
Year 
% 
Sur 
5 
Year 
% 
Sur 
7 
Year 
% 
Sur
Survival 
KP 
162 
(61,101) 
0.21 
(0.64) 
0.02 
(0.87) 
0.96 
(0.58,1.6)    
Low-KP 
67 
(26, 41)    
69.95
% 
55.28
% 
29.94
% 
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Table 11 (Continued)      
High-KP 
95 
(35, 60)    
72.25
% 
56.41
% 
23.81
% 
Low-KS 
68 
(26, 42)    
70.40
% 
55.64
% 
29.67
% 
High-KS 
94 
(35, 59)    
71.95
% 
56.18
% 
23.71
% 
Survival 
PI 
162 
(61,101) 
1.01 
(0.31) 
2.23  
(0.13) 
1.49 
(0.88, 2.5)    
Low-PI 
76 
(27, 49)    
74.77
% 
64.13
% 
33.23
% 
High-PI 
89 
(34, 52)    
69.69
% 
44.65
% 
33.49
% 
Survival 
PP 
162 
(61, 101) 
0.52 
(0.46) 
0.15  
(0.69) 
0.90 
(0.55, 1.5)    
Low-PP 
72 
(30, 42)    
67.91
% 
53.60
% 
31.26
% 
 
High-PP 
90      
(31, 59)    
74.00
% 
57.74
% 
22.50
% 
Survival 
PS 
162 
(61,101) 
0.26 
(0.61) 
0.61  
(0.43) 
1.23 
(0.7, 2.07)    
Low-PS 
77 
(30, 47)    
72.39
% 
59.95
% 
31.06
% 
High-PS 
85 
(31, 54)    
70.26
% 
48.96
% 
36.72
% 
 
The analysis of this population of stage I NSCLC patients is continued in the following 
chapter using the novel statistical learning (SL) methods. 
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Chapter 4: A Fusion of Statistical Learning Techniques with Accepted 
Epidemiologic Applications 
 
4.1 Background 
Statistical learning (SL) techniques with kernel mappings can provide benefits when 
addressing  complicated decision problems [26-28]. These techniques are capable of 
capturing non-linear input-output characteristics, operating on small datasets with 
feature correlation, and do not require modeling or distribution assumptions. These 
attributes are not derived without tradeoffs. These methods do not provide an output that 
has a useful epidemiologic interpretation and their training often requires specialized 
techniques.  In contrast, logistic regression (LR) modeling, Kaplan-Meier analysis, and 
Cox regression provide important epidemiologic interpretations and are used extensively 
due to their availability.  
 
The goal of this work primarily was to demonstrate and evaluate a method of fusing SL 
with accepted epidemiologic practice using this dataset of lung cancer patients as an 
example and test-bed. The work in this chapter was excerpted from Behera et al [19]. To 
meet this objective, it was necessary to develop a platform to implement kernel based 
SL methods efficiently, which will also support future studies.  A technique validated 
here, (applied in Chapter 2) was used as an efficiency gain.  This shows that either non-
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parametric Az analysis (i.e. without modeling) or LR in conjunction with Az analysis can 
be used as a sifting or filtering mechanism to find variables that  influence the probability 
of survival characterized by either HRs or Kaplan-Meier comparisons.  Although the LR 
model fusion with SL provides an important interpretation and application in its own right, 
it is relatively simple to estimate Az within our programming language, whereas 
incorporating Cox regression or Kaplan Meier analysis as intermediary steps within our 
processing routines would require considerable code development. Thus, the use of 
binary separation analysis (used in the favorable outcome modeling) in conjunction with 
SL based survival analysis also represents an import efficiency step in the hybrid 
analysis.  
 
To adapt SL methodology for epidemiologic application, a probabilistic neural network 
(PNN) [29] was combined with LR modeling and  survival analyses (i.e. Kaplan-Meier 
analysis and Cox regression) to demonstrate the concept.  This hybrid approach 
combines the strengths of the SL methodology with these important epidemiologic 
techniques.   The PNN is a statistically inspired neural network [29] that uses a kernel 
mapping [30, 31] to estimate the underlying probabilities.  The PNN was adapted to 
provide a patient score, which is different use than its intended classification application. 
For the LR modeling comparisons, the favorable and unfavorable group analysis 
presented in Chapter 2 was used to dichotomize the patient population for the LR 
analysis.  Raw clinical variables were used to form a new patient score variable with the 
modified PNN. Additionally, the PNN output (i.e. the patient score) was used as the input 
variable for survival analysis. There are weight parameters within the PNN (i.e. the 
kernel sigma-weights) that must be estimated properly. Differential Evolution (DE) was 
used for this optimization problem [32]. DE is an evolutionary computing strategy for  
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global optimization tasks.  Because the dataset was limited, stochastic methods were 
developed to provide feedback to the DE optimization and to derive the patient PNN 
scores.  This new system was also evaluated with the simulated datasets and methods 
described previously [33]. 
 
4.2 Methods: Modeling Techniques  
4.2.1 Favorable Outcome and Survival Analysis  
The non-interaction LR model [34] was used to predict favorable and unfavorable 
survival outcome (explained in detail in Chapter 2).  Although the work in this chapter is 
presented after the work in chapters 2-3, it was performed at an earlier date [19]. The 
dataset was constructed by considering those patients that has complete ascertainment 
for smoking status, age, grade, and gender.  For the LR analysis, we formed incident 
(n=59) and censored (n=92) groups as in Chapter 2.  This dataset was similar with the 
various subgroups described in Chapter 2.   Three variables were used in the analysis. 
Age and grade were combined with the PNN to form a hybrid variable labeled as the 
patient-score. Gender was incorporated as a controlling variable. The patient-score was 
used as the input to LR and survival analysis (Cox regression and Kaplan Meier 
Analysis).  The reasons for combing age and grade are as follows. Grade showed weak 
association in the previous analysis (i.e. trend only). This could imply either the 
association is truly weak or it exists and could not be captured by a linear technique. 
Moreover, age is continuous, and grade can be considered as a three-state continuous 
variable both amenable for probability modeling, whereas the other categorical variables 
do not (strictly) lend themselves to probability modeling. The hybrid variable modeling 
was compared with the accepted approaches (LR and survival analysis) using age, 
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grade, and gender as the inputs. In this survival analysis, patient strata were formed by 
choosing the median age and median PNN score as the separation points. The other 
relevant variables were introduced with both age and PNN score to evaluate their 
influence on the respective survival probability curves.  
 
As previously, for the LR modeling comparisons, ORs were used to assess 
measurement association with 95% CIs and Az  was used to assess  predictive 
capability.    For age and PNN score (i.e. the continuous variables), the LR model 
coefficients were re-scaled to provide ORs per SD change for each variable. The ORs 
for grade were cited in per unit increase. The Az was estimated with three methods. 
First, to assess the SL training and patient scores, the definition of Az was applied [35] 
using the respective distributions.  Secondly, the Az quantities for the LR models were 
generated within SAS as described in Chapter 2 using the output of the LR model (same 
interpretation as provided by the first method).  For the Kaplan-Meier analysis, chi-
square Wilcoxon (more sensitive to shorter term survival differences) and log-rank (more 
sensitive to longer term survival differences) tests were used for differences in 
stratification.  Hazard ratios with 95% CIs were estimated with Cox Regression.  Thirdly,  
Az was also derived from Cox regression and is a measure of the agreement between 
the model and actual time-to-event outcome [36], which is a different interpretation.     
 
4.2.2 Probabilistic Neural Network and Kernel Methods  
A variation of the PNN was implemented using a Gaussian kernel, although there are 
many kernels meeting the established criteria [37].  Paralleling our earlier work [38], the 
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distance metric for a d dimensional input vector (i.e. the relevant patient variables) is 
given by 

 

d
1j
2
j
2
ijj
i
)ww(
)(D w ,                 Eq. (1) 
where i is the patient index, wij  is the jth component of the ith sample’s input vector, and 
wj is the jth component of a  prospective test sample’s input vector w. The sigma-weights, 
σj , were estimated with  DE optimization. Specifically, d = 2, with wi1 = age, and wi2 = 
grade for the ith patient.  The probability density estimation [30, 31] for w with n training 
samples is expressed as   
),(k
n
1)](Dexp[
n
1)(g
n
1i
i
n
1i
i 

 wwww .              Eq. (2) 
Normalization factors (ignored) are discussed below. The PNN was constructed with the 
above formulism for each group.  For group-1, the density for w is given by 
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.             Eq. (3)   
For a given w, the sum on wi is taken over group-1 samples only with n = n1. The g2(w) 
density was estimated the same way by restricting the sum on wi to the group-2 samples 
with n = n2.  In both the g1 and g2 estimations, w included samples from both groups. 
Equation (3) [i.e. the kernel mapping] also represents a function mapping of the vectors 
w and wi , where each element  (for fixed i) of the summation represents the inner 
product of the mapped vectors [28], rendering a nonlinear problem tractable with the 
proper choice of kernel. Assuming prior probabilities and misclassification costs are 
equal, the PNN classifier [29] is expressed as  
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where c is a constant.  For classification when this condition is met, w belongs to group-
1. Because we were interested in developing a score for each patient (not classification), 
we formed a score with the above expression given by 
patient-score = 
)(g
)(g
2
1
w
w
 .      Eq. (5) 
The multivariate normalization factors were not important for this application because 
both g1 and g2 contained the same sigma-weights. These scores were used with LR 
modeling and the survival analysis. Because the above expression is always positive 
and can be large, we used z =  ln (patient-score) in the analyses as the PNN derived 
patient score and performed a range compression technique to reduce statistical outlier 
interference in the LR modeling.  
 
4.2.3 Probabilistic Neural Network Training and Operation 
A stochastic cross-validation technique was developed in combination with DE to 
estimate the sigma-weights for the kernel in the PNN.  DE is a stochastic global 
optimization strategy that is self-organizing via feedback and represents an evolutionary 
process.  An algorithm described by the founders of DE [32] was developed and their 
notation is used in this work. Important points underlying DE were discussed in our 
previous work [38] and are briefly discussed here.  A uniform crossover Cr = 0.9 and 
scale factor F = 0.2 were used as starting points. The zero-generation vector population 
(i.e. NP = 40 vectors) was initialized with uniformly distributed random variables with 
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components constrained to this range [0.01, 1.5]. The vector’s components are the two 
sigma-weights. For a given generation, the DE process constructs a mutant vector (or 
vg) by stochastic perturbation from the current population of x, where g is the generation 
index.  From this, a candidate vector (or ug ) is constructed that competes with a given 
current generation vector, xg ,  selected at random in such a way that it was not involved 
with the vg (or ug ) construction. Possible solutions (xg and ug) compete against each 
other using feedback from the optimization problem.  The winner moves to the next 
generation of x (i.e. the g+1 generation).  For a given generation, there are NP 
competitions. In this DE application, Az was the feedback measure using the two 
patient-score distributions (i.e. for the censored and incident groups) derived from Eq. 
(5). The feedback to the DE was formed by ensemble averaging derived with bootstrap 
sampling [39]. For one DE generation, Nt bootstrap populations were generated. To form 
a given bootstrap population, n2 samples were selected randomly from group-1 and from 
group-2 with replacement. We keyed on n2 as not to bias the sampling to the larger 
population. One sample from each class was selected randomly and used as w in Eq. 
(5) to generate the respective patient-score quantities. The remaining samples were 
used to build the respective wi populations in Eq. (5). We refer to this process as a leave 
two-out stochastic cross-validation technique. When Nt = 1, the process is somewhat 
similar to the conventional leave two-out approach using different realizations of the 
population.  This process was then repeated Nt (i.e. training) times and the average Az 
was used as feedback for one DE generation.  The process was terminated after G 
generations. The weights that provided the largest Az were carried over to the analysis 
and used to generate z for each patient using stochastic methods and ensemble 
averaging.  For a given w, a bootstrap population was generated from the wi  population 
and the respective z was generated for all n1 and n2 patients.  Each patient’s z was 
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derived from ensemble averaging by repeating this process for Nsc times. The training 
process and final score generation flow are shown in the Figure 6 schema. The software 
for the PNN and DE applications was developed recently [19] using the IDL (ITT Visual 
Information Solutions, Boulder CL) programming language.  
 
 
Figure 6: Modified probabilistic neural network (PNN) stochastic training and z 
generation. This schema shows the PNN training for the Differential Evolution (DE) 
sigma-weight vector construction, competition, and feedback from the g to the g+1  
populations. The sigma-weight vectors xg and ug compete for the next generation.  The 
receiver operating characteristic curve area (Az ) from the stochastic cross-validation is 
derived with ensemble averaging to reduce the chance of passing outliers back to the 
vector competition.   When g = G, the evolution stops and the sigma-weights are used in 
the PNN to generate z for each patient stochastically with ensemble averaging. The z 
quantities are then passed to the survival and logistic regression analyses.  
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4.3  Results 
4.3.1 Favorable Outcomes  
The patient characteristics for this specific data subset were statistically similar to those 
described in Chapter 2 and are not shown. For specific comparison reference, the 
associations from the LR model (i.e. accepted approach) with age, grade, and gender 
were estimated for this data subset and are provided in top portion of Table 12 for easy 
reference, which are similar to those provided in Chapter 2. In the univariate age model 
(Az = 0.636), the age OR = 0.60 was significant.  In the grade adjusted model (Az = 
0.657), the OR for age was similar and the grade OR = 0.68 was not significant. In the 
grade and gender adjusted model (Az = 0.703), the age OR = 0.63 and gender OR = 
0.38 were significant, whereas the grade OR = 0.73 was not significant.   
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Table 12:  Odds ratios.  The odds ratios (ORs) and 95% confidence intervals are 
provided parenthetically for the variables used in the logistic regression modeling.   The 
ORs for the continuous variables (age and z) are cited per standard deviation (SD) 
increase in the respective variable or as a unit increase (grade) while controlling for the 
other variables when applicable.  The z variable includes grade and age simultaneously.  
The ORs for the other covariates (Cov) are listed in the column to the right. The area 
under the receiver operating characteristic curve (Az) is also provided for each model. 
Model SD Age OR Az Cov Unit Cov OR 
Accepted               
Age 8.681 
0.60 
(0.42,0.86) 
0.636    
Grade 
adjusted 
8.681 
0.58  
(0.40, .83) 
0.657 Grade 1 
0.68  
(0.40, 1.15) 
Grade and 
Gender 
adjusted 
8.681 
0.63  
(0.43, 0.91)
0.703 Grade 1 
0.73  
(0.42, 1.25) 
        Gender
Male 
vs 
Female 
0.38  
(0.19, 0.78) 
Model SD ln(z) OR Az Cov Unit Cov OR 
 Hybrid              
z (Age and 
Grade) 
1.695 
4.15  
(2.15, 8.01)
0.763    
Gender 
adjusted 1.695 
3.67  
(1.88, 7.16)
0.778 Gender
Male 
vs. 
Female 
0.50  
(0.24, 1.05) 
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The DE training for the modified PNN resulted in two sigma-weights with σ1 = 
0.013610961 and σ2 = 0.35805283 for age and grade, respectively. Using Nt = 1 
produced training Az values between 0.700-0.830. Choosing Nt = 5 gave consistent 
findings and was used in the analysis. The stochastic cross-validation performance 
coinciding with these weights gave Az = 0.710 with SE=0.03 after three generations (G = 
3). These parameters were used to generate z for each patient with Nsc= 20. Processing 
age and grade separately through the PNN gave Az = 0.656 for age and Az = 0.538 for 
grade, which are similar to the Az values when assessing these variables individually 
with LR modeling (shown in Chapter 2).   
 
The continuous hybrid LR findings are shown in the bottom of Table 12.  The combined 
effect shows that for a SD increase in z (SD=1.69), the respective patient is about 4.15  
times more likely to experience a favorable survival outcome (or incident group member 
is 0.24 more likely to experience a favorable outcome) with Az = 0.763, which was 
significantly larger (p = 0.0062) than that provided by the respective age and grade LR 
model. Due to the way the PNN was defined, increasing z was protective, whereas 
increasing in age was not. Adjusting for gender increased the predictive capability of the 
model with Az = 0.778 (SE = 0.03), although the gender OR lost significance.   Gender 
also reduced the association for z with OR = 3.67 per standard deviation increase, which 
was a stronger association than provided by age in the corresponding model. The Az 
derived from the hybrid model (z and gender) was significantly greater than that of the 
corresponding LR model with age, grade, and gender (p = 0.0173).    
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To evaluate the effect of the kernel mapping on age and grade, the LR model outputs for 
the two models were plotted as a function of grade and age.   The left side of Figure 7 
shows the grade plots for the LR (accepted approach with age and grade) model.   The 
respective grade plots for the hybrid LR model using z (age and grade combined) are 
shown on the right side of Figure 7.  In these plots, black was used to denote censored 
group samples and red to denote incident group samples. The grade 1 plots for both 
models exhibit similar behavior for the lower ages and show that patients 65 years of 
age and younger are more likely to be in censored group.   The hybrid model separates 
some older grade 1 patients in contrast with the accepted LR model.  A comparison of 
the grade 2 plots shows that the hybrid model provides separation for the younger, 
middle age, and some upper age patients, whereas the respective accepted LR model 
produces confusion between the groups.  In the grade 3 plots, both models provide 
separation for lower age patients, whereas the hybrid model shows group separation in 
the middle-age range as well. Because z is a composite variable and difficult to interpret, 
the associations between age, grade, z, and group status shown in Figure 7 are also 
summarized in Table 13.  This provides the average values for age and the z variables 
separated by grade and group.  
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Figure 7: Logistic regression model output plots for each tumor-grade (1-3). The plots 
on the left show the logistic regression model probabilities (P) using the age and grade 
variables as the model inputs for each tumor grade.  The plots on the right show the 
respective hybrid logistic regression model probabilities (P) using the variable z (i.e. age 
and grade combined with the probabilistic neural network) as the model input.  Because 
there are overlapping points (patients with the same grade and age), some points are 
not distinguishable. The censored group (black) is compared with the incident group 
(red). The curves were fitted with a cubic spline. 
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Table 13: Age and z relationships. This table gives the mean values for age and z as a 
function of tumor-grade (Grade) and censored/incident group status and combined total. 
The number (n) of patients in each category is also provided.   
Censored Grade 1 
Grade 
2 
Grade 
3 
Total 
n 17 49 26 92 
Age (mean) 66.41 66.27 63.19 65.42 
z  (mean) 2.11 3.91 3.12 3.36 
     
Incident Grade 1 
Grade 
2 
Grade 
3 All 
n 6 34 19 59 
Age (mean) 73.83 68.88 69.47 69.58 
z  (mean) 0.26 1.37 -0.07 0.8 
 
As in the previous chapters, the overall survival (OS) and censor times were used to 
form two groups because of the separation between the respective distribution means. 
The favorable group had a mean censor time of 3.97 years (i.e. mean known OS time, 
which is a low-side limit assuming these patients did not expire the day after study-
contact), whereas the incident group had a mean OS time of 2.20 years (data not 
shown). The minimum censor time (2.35 years) is greater than the mean OS time for the 
incident group indicating validity of the dichotomization method, which is discussed in 
more detail in Chapter 6.    
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4.3.2 Survival Analysis  
As above, the results from the standard methods of survival analysis are presented first. 
The relevant findings for comparison are in Table 14.  The hazard for age was HR = 1.72 
indicating that upper-age group membership is significantly more hazardous than lower-
age group membership. The longer-term survival is significantly different between the 
two age groups (p < 0.050). Including grade induced a greater hazard with HR = 1.78, 
but the change in the survival curves (not shown) when controlling for grade was not 
significant in either the short term (p = 0.074) or the longer-term (p = 0.091).  The 
addition of gender caused a significant change in  the survival curves compared with age 
alone for both the short term (p < 0.002) and long-term survival (p < 0.005) but the HR = 
1.64 lost significance (curves not shown). The grade and gender adjusted hazard for age 
was HR = 1.68 (also lost significance). The statistical test findings for age and gender 
are provided in Table 14 (top rows).  The survival probability curves for z are shown in 
Figure 8 and the HRs are provided in Table 14.  The findings from these accepted 
approaches follow those from Chapter 2 and are presented here for reference.  
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Table 14: Hazard relationships for dichotomous age and z. For the age and z variables, 
two groups were formed using the respective distribution median as the cut-point and 
compared.  The hazard ratios (HRs) are provided with 95% confidence intervals 
parenthetically. The area under the receiver operating characteristic curves (Azs) 
derived from Cox regression models are also provided. Because age and z translate 
inversely with respect to hazard, increased age confers a greater hazard while 
decreased z confers a greater hazard. To make HR comparisons of z with age, the 
reciprocal of the z HR is required. 
Model Age HR Az 
 Accepted    
Dichotomous Age 1.72 (1.02, 2.90) 0.5792 
Grade adjusted 1.78 (1.06, 3.02) 0.606 
Gender adjusted 1.64 (0.96, 2.78) 0.669 
Grade Gender 
adjusted 
1.68 (0.99, 2.85) 0.677 
   
Model z HR Az 
 Hybrid    
Dichotomous z 0.25 (0.14, 0.47) 0.691 
Gender adjusted 0.28 (0.15, 0.53) 0.738 
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Figure 8: Survival probability curves for z.  The upper and lower-z groups were formed 
by dichotomizing the total collection of patients at their median z value. The upper-z 
group (upper brown curve) exhibits better survival characteristics than the lower-z group 
(bottom blue curve). These findings incorporate tumor-grade with age via the 
probabilistic neural network combination.    
 
 
The hybrid survival analysis is to be compared with the accepted approach. There is a 
significant survival difference between these upper and lower-z groups (i.e combination 
of age and grade) both in the short term (p < 0.0001) and long term (p < 0.0001) with HR 
= 0.25 indicating those in the upper-z group are at a significantly reduced hazard 
compared with those in the lower z group (i.e. the hazard for those in the lower-z 
membership was HR = 4.0). About 52% of the upper-z group survived past 7 years, 
whereas as about 11% of the lower-z group survived past this time.  In comparison, 37% 
of the lower-age (when controlling for grade) group survived past 7 years, whereas 
about 29% of the upper-age group survived past this time. The addition of gender also 
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produced a significant change in both short term (p = 0.0146) and the longer term (p = 
0.0319) with HR = 0.28 (HR = 3.57 for lower-z membership).  The associated statistical 
comparisons for z and gender are provided in Table 15 (bottom two rows). As shown in 
Table 14, the hybrid Cox model (i.e. using z) showed greater concordance (Az  =  0.691) 
with the outcome than that of the Cox model (accepted approach) using age and grade 
(Az = 0.606 ), but the difference in Az was a trend (p = 0.056).   Likewise, the Az 
comparison between the hybrid Cox model using z and gender (Az = 0.738) with the Cox 
model using age, grade, and gender (Az = 0.677)  showed a similar trend (p = 0.0747).  
 
Table 15:  Survival probability statistical test summaries.  The statistical tests findings 
(Chi-square and p-values) for the various age and z related survival probability curves 
are provided with the degrees of freedom (DF).  When comparing more than two survival 
curves (*), the hypothesis that all the curves were the same was tested against the 
alternative that at least one curve was different.  
Model Test Chi-Sq DF p-val 
Accepted     
Dichotomous Age over 
Strata 
Log-Rank 4.178 1 0.0409 
Wilcoxon 3.407 1 0.0649 
Dichotomous Age and 
Gender over Strata 
Log-Rank 12.738 3 0.0052* 
Wilcoxon 13.511 3 0.0043* 
Hybrid     
Dichotomous z over Strata Log-Rank 22.759 1 <0.0001 
 Wilcoxon 14.941 1 0.0001 
Dichotomous z and 
Gender over Strata 
Log-Rank 28.186 3 <0.0001* 
Wilcoxon 22.488 3 <0.0001* 
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4.3.3 Additional Validation Analysis 
4.3.3.1 Simulation Evaluation 
 A simulation was performed to assess the training, optimization, and patient scoring 
system shown in Figure 4 under ideal conditions. The same simulation described 
previously [33] was used as the input to the modified PNN. This is a two-class simulation 
with two correlated input measurements and a non-linear separation boundary.  Two 
hundred samples per class were generated giving 400 samples total as previously [33] 
for the training dataset. The training dataset was used to estimate the sigma-weights 
using the algorithm described above (Figure 6). We used the same stochastic averaging 
(N t= 5, and Nsc = 20) and bootstrap methods.  We stopped the differential evolution 
optimization for G=3 as above, which gave two sigma-weights (0.291156797, 
0.0872920) with a training Az = 0.987.  The training dataset was then used for wi  in the 
score generation using independent data.  We then simulated an evaluation dataset of 
the same dimension (200 per class giving 400 samples total) that was not used in the 
sigma-weight generation. These new samples were then used as w in the stochastic 
score generation and evaluated. This evaluation gave Az = 0.979.  This shows in 
principle, the system is viable and that the training distribution must be representative of 
the population. It is also worth noting that the separation provided by this modified PNN 
system was larger than that described previously using a different statistical learning 
system when processing the same type of simulated datasets (i.e. Az  ≈ 0.950).  
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4.3.3.2 Traditional Holdout Cross-Validation 
To assess the internal validity of the PNN score approach, we used the schema shown 
in Figure 6 with one main difference. Two patient samples (one sample from each group) 
were selected at random and held out (i.e. leave two-out cross-validation) of the training 
process. To slow the DE convergence, we set Cr = 0.1. The system comprised of the 
remaining n-2 patients was trained for 20 DE generations for each holdout pair.  These 
n-2 samples were used for training and for generating training z scores (age combined 
with grade with the PNN) and Azs. For each DE generation, a bootstrap population was 
generated from the fixed n-2 population and an Az was generated.  The weights that 
gave the largest Az for the 20 DE generations were used to generate the z scores for the 
two samples (holdout pair).  We used stochastic averaging for the output scores, where 
20 bootstrap populations were generated from the fixed n-2 training samples (generated 
20 scores for each of the two left out samples). This process cycled (i.e. choosing 
another pair at random leaving a new n-2 training population for the next 20 DE 
generations) until all patients received a score. The resulting leave two out cross-
validations gave Az = 0.700 (i.e. similar to the Az estimated from the score generation), 
indicating the approach was internally valid, when generating scores for samples not 
observed by the system during the training process.  
 
4.4 Brief Statistical Learning Summary  
An SL methodology comprised of DE optimization, a kernel mapping, and stochastic 
ensemble averaging was presented as an illustration to generalize widely used analysis 
techniques. The technique gives the SL methodology an epidemiologic interpretation. 
Although a specific example was used in this work, the framework applies to all 
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situations where LR modeling and survival analysis are appropriate. The approach can 
be easily modified to include as many input variables as required and new samples can 
be added into the training procedure with the proper clinical feedback indicating the 
system can learn continually without computer processing demands due to its relative 
simplicity.   The system will require further evaluation with different datasets before it can 
be applied in practice.  
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Chapter 5: A System for Automated Measurements and Analysis of Tissue 
Microarray Image Data 
 
There are two aims of this tissue microarray (TMA) investigation. The first aim is to 
develop a method of preparing and preprocessing the raw image data to allow 
automated measurements for the analysis of the multispectral TMA images. The second 
aim is to investigate whether various automated measures are related to some pre-
defined endpoints. These endpoints may be survival, histology type, or tumor-grade for 
example. That is, the goal is to explore the possibility of capturing different information 
automatically than what a pathologist distills from tissue sections by inspection. This 
work analyzes high-throughput TMA arrays stained with routine antibodies used in 
pathology. This is used as developmental work and a test-bed to address the first aim. In 
meeting the first aim, a framework or protocol is established for preparing TMA images 
to investigate novel protein stains as potential biomarkers in the near future. Due to 
technical limitations, low resolution TMA images were investigated at this time. The 
intent of this preliminary investigation is to develop methods that scale easily and are 
applicable to higher resolutions.  
 
5.1 TMA Technology   
Traditionally, pathology evaluation was performed with stained whole sections on slides. 
Tissue microarray technology, digital pathology, and virtual microscopes are newer 
additions to the pathology toolset and are widely used for research purposes. Briefly, the 
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TMA construction is initiated by the pathologist’s input. Areas of interest are identified on 
the H&E stained tissue sections by a pathologist. Tissue cores are obtained from the 
corresponding areas of the originating formalin fixed paraffin embedded tissue block 
using a semi-automated tissue microarrayer. Multiple tumor tissue cores (i.e. core 
biopsies using a needle) are often taken to account for possible tumor heterogeneity.  
Tissue cores are then transferred to a recipient wax block. Each recipient block contains 
tissue cores from multiple patients, arranged in an array pattern. Sections of the 
recipient microarray block are cut using a microtome and analyzed using standard 
histological immunohistochemical stains (see Figure 9).   
 
 
Figure 9: Raw TMA image. Three tumor cores and one normal core were taken from 
each patient. This array contains cores from 27 patients. Each full row corresponds to 
three patients (i.e. 12 core samples with four samples per patient). The lone sample at 
the top left is an arbitrary spotter marker defining the proper orientation of the image.  
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In this work, the digitized scans of TMA sections were obtained using the Nanozoomer 
2.0 HT whole slide scanner (Hamamatsu, USA). The NanoZoomer is capable of high 
magnification up to 40x objective and can process up to 210 slides at once. The 
NanoZoomer uses 3-chip TDI (Time Delay Integration) line scanning method, which 
accurately reproduces sample colors. The line scanning method enables the quick 
production of high resolution digital slides.  
 
5.2 TMA Image Description and Preprocessing  
The TMA arrays were scanned with 20x magnification and digitized with 0.453μm per 
pixel spatial resolution. A free software (Olympus, Richmond Hill, Ontario) was used to 
convert the original NDPI format (i.e Hamamatsu format) images to a format (i.e. Tagged 
Image File Format or TIFF) compatible with our programming language (IDL Version 8.1, 
ITT Visual Information Solutions, Colorado).  The converted images are multispectral 
data comprised of red, green, and blue (RGB) component lower resolution images each 
with 8 bits per-pixel dynamic range with 21.1μm per pixel spatial resolution.  Each image 
is 1280 ×1024 pixels in dimension.  Each disc (i.e tissue core) is approximately 55-60 
pixels in diameter and the disc spacing (separation) is about 30 pixels.  Each slide of 
TMA contains multiple core sections from 27 patients, as compared to the traditional 
method where a section of tissue from a patient is on a single slide and reviewed by the 
pathologist. The TMA allows a pathologist to evaluate several patients with a single slide 
viewing. 
 
To address aim one, operator input was combined with automated processing to prepare 
or preprocess the TMA images for automated analysis.  The operator input serves as a 
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quality control mechanism. In principle, the arrays have four stained sections for each 
patient most of which have thee malignant tissue sections (samples) and one normal 
tissue control section.  However, not all samples allowed for a normal control tissue 
sample, leaving four malignant sections for some patients. Moreover, not all sections 
were viable for automated analysis for various reasons (e.g. missing sections or over 
contrast).  The sections for a given patient are adjacent row-wise (in the horizontal 
direction) to each other with 12 sections (i.e. cores) per row (three patients) with 9 rows 
on a given full TMA image array.  Our database has seven full TMA images and one 
partially filled image.  The rows do not necessarily run parallel to the image borders (as 
exemplified in Figure 9) in most images. Samples for some patients were missing due to 
poor staining and some sections for given patient were missing.   The patient labeling 
that relates to the sections on the image is maintained in a spreadsheet (secondarily to 
the web-based database described previously). That is, the images do not contain 
patient identification information. Thus, a correspondence between the image data and 
patient identification (IDs) must be established.   
 
The first step in connecting the image with the patient was to orient (or check) the 
images in the proper representation and then inspect the images. The one isolated 
section on the top left in Figure 9 is a spotter core (i.e an arbitrary sample) indicating that 
the image is in the proper orientation. The red image (arbitrary) was used for the 
preprocessing analysis. The layout of a given image was sketched on paper and each 
section was labeled in accordance with the key spreadsheet containing the patient IDs. 
A given image was inspected with the aim of finding one viable tumor section per 
patient, because many of the normal sections were not viable. The first choice was to 
select a section that was intact (appeared as a uniform disc) without background 
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interference (i.e. without over contrast due to missing tissue).  The core sections were 
counted across each row for a given image, and the viable sections were marked on the 
sketch.  
 
The next step was automated. The background (i.e. non core sections of the image) was 
segmented from the tumor section images.  Segmentation was achieved with a static 
pixel value threshold = 220, determined empirically. In this step, all pixel values less than 
220 were set to zero.  After this step, the tumor sections were separated from 
background along with some stray smaller sections scattered about.  In the next step, a 
label region algorithm (IDL routine) was applied to the segmented image that sets each 
contiguous (i.e. blobs) non-zero region within the image to a specific but arbitrary value. 
Thus, all contiguous sections (all pixels within the section) in a given image now have a 
unique but arbitrary value.  
 
The following step was semi-automated. An interactive program was developed where 
the operator views the image and selects the one (pre-selected) section per-patient 
(using the sketch as guide) by clicking on the section.  At this time (after the respective 
mouse click),  the computer program reads the pixel values from the selected region and 
makes a mask by replacing the original pixel values for the selected region with values 
equal to the patient’s ID (respective IDs were coded into the program).  This process is 
repeated until reaching the last sample on the respective TMA image; all of the non-
selected regions are discarded during this process.  This results in a mask (shown in 
Figure 10, left), where each patient’s tumor section is labeled with their ID number (all 
the pixels within the section have the patient’s ID number as their value).  The mask is 
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then inspected by sampling regions from it and making comparisons with the original 
array and the sketch.  Once developing the protocol described above, this procedure 
takes about thirty minutes per microarray image. The same mask works for the green 
and blue images because the three images are spatially aligned. 
 
 
Figure 10: The mask images of the TMA image shown in Figure 9. Each patient’s tumor 
section is labeled with the patient’s identification number (all the pixels within the section 
have the patient’s identification number as their value) to form the binary mask (left). To 
reduce edge effects further, each section was eroded in the binary-mask to account for 
the filter kernel length (right). These images are over contrasted (all non-zero pixel 
values set to a constant) for illustration purposes so all samples can be observed 
simultaneously. 
 
5.3 Automated Image Analysis Methods  
When analyzing a given image, the patient-mask is used as a guide to acquire the 
information for a given patient automatically.  This works well for calculations such as 
averages, standard deviations or pixel differences.  Modifications are required when 
applying filter kernels to analyze textures because of edge effects. Filter kernels of 
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length five were used (described below). To reduce edge effects, the raw microarray 
image was first filtered with the background intact, because the background was closer 
to the section intensity level than that of the zero background.  To achieve the final 
selection, two related masks were used. From the patient-ID-mask, a binary mask was 
formed by converting all non-zero valued pixels to unity giving a binary-mask.  To reduce 
edge effects further, each section was eroded in the binary-mask (contains the selected 
samples only) to account for the filter kernel length. The final patient labeled mask 
(shown in Figure 10, right) is given by: final patient-mask = eroded binary mask × the 
patient ID labeled mask.  The raw TMA images (red, green and blue) are then filtered 
separately. The portion of the filtered image used in the analysis is then given by:  
eroded binary mask × filtered raw TMA image.  It was noted that the sections in the raw 
image are spaced about thirty pixels apart indicating that the five element kernels cannot 
span across two sections simultaneously. For a given filtered section, the standard 
deviation was used as the summary measure. If kernels of larger extent were used a 
simple modification is required:  one section could be segmented in isolation by 
embedding  (center) it in a sufficiently large zero-background image, apply the filter, and 
then use the same steps above modified to operate on one section at a time.  
 
The automated image analysis considered measures derived from the raw images such 
as the average (M), standard deviation (SD), and differences in pixel values between the 
multispectral images. For reference each pixel has red, green, and blue components 
which are defined as the vector (x1, x2, x3) = (red pixel value, green pixel value, blue 
pixel value).  Laws texture filters [40] were also applied to these images to assess 
whether textures are related to the various outcomes. For completeness, the Laws filter 
set is comprised of five one dimensional kernels. Each kernel has five elements 
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expressed as:  L= (1,2,6,4,1). E=(-1.-2,0,2,1), S=(-1,0,2,0,-1),  and W=(-1,2,0,-2,1), 
R=(1,-4,6,-4,1) referred to as level (L) , edge (E) , spot (S), wave (W), and ripple (R), 
respectively.  This naming convention describes the textures captured by each kernel. A 
half-band filter was also applied defined as Bh = (-1,1). These filters are generically 
referred to as f below and are k × 1 (k = 5 or k= 2) element column vectors. The two-
dimension filter kernels are obtained by the outer product of any two filters given they 
have the same number of elements in this application. The two dimensional kernels are 
defined as,  
T
jiffH  ,          Eq. (6) 
where T indicates transpose and the indices define arbitrary filters (i.e. i = E and   j= E, 
or i = E  and j = W]. For this work, we investigated two dimensional filters for i = j only.  
These filters were applied to the red, green, and blue components for given section 
independently. For a given binary output (i.e. AC or SQ for example), the T-test is used 
to compare the measures across the two groups. After applying the filter operation, a 
given component section was summarized as the standard deviation of the filtered pixel 
values.   
 
Because the multispectral data is correlated, Principal Component Analysis (PCA) [41] 
was also applied to each section to reduce the three component images to one image. 
For a given section, PCA was applied at pixel level and at the summary level, where the 
summary measures across all samples were included.  At the section or pixel level, (x1, 
x2, x3) were used from a given section as the input. Assume there are m pixels in a given 
section then the matrix X is an m × 3 matrix with the rows defined as xi= (x1, x2, x3)i for i = 
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1 through m rows (i.e. number of pixels within the specific section). The respective 
column mean is first removed from each column, and the column centered matrix is 
redefined as X.  The covariance matrix of X is given by  
T
m
1 XXC               Eq. (7)   
The Eigenvalues and Eigenvectors of C were calculated. The vector with the largest 
Eigenvalue = Ep  (i.e. the principal component) was used to form a new section from the 
three component images by the inner product: new section = < xi , Ep>  for all i.  At the 
summary level, the same analysis applies with the proper relabeling.  Now we let m = 
the number of patient samples and define the vector σi =( σ1, σ2, σ3,)i  where i is the 
patient index. The components [i.e. σ1, σ2, and σ3] represent the standard deviation 
calculated from a given filter output or from a mixture of filter outputs for a given section. 
The matrix X is formed with the rows defined as σi and the same analysis is performed.  
 
5.4  Results  
5.4.1 Tumor Histology Subtype Analysis 
Because the previous work showed a survival advantage for those with AC (n=72) 
compared with SCC (n=39), the measures between patients with these two histological 
subtypes were compared. This data subset was developed by considering patients with 
AC and SCC histology that had full ascertainment for the TMA data.  Image examples 
for AC and SCC are shown in Figure 11. The results from raw image analysis are 
summarized in Table 16. 
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Figure 11: Raw images of SCC and AC. This shows single tumor cores from SCC (left) 
and AC (right) patients from the TMA. 
 
Table 16: Feature analysis. This gives the p-values from the T-test when comparing 
patients with AC and SC. From left to right, we compared the mean intensity (M), the 
standard deviation (SD) and four x-y symmetric Laws filters (i.e. the outer product of a 
given filter with its transpose) and the x-y symmetric half-band filter.  The left column 
indicates the spectral component image that was filtered.   
 M SD EE SS WW RR BhBh 
x1 0.2637 0.8047 0.4310 0.1163 0.0430 0.0398 0.0514 
x2 0.3118 0.7715 0.2779 0.0466 0.0184 0.0243 0.0224 
x3 0.3109 0.5260 0.2903 0.0765 0.0382 0.0402 0.0448 
 
The band pass filters from right to left are ordered from high-frequency to low-frequency 
band-pass with RR and BhBh both having similar high-frequency band-pass 
characteristics. The findings show that the higher frequency filters (WW, RR, and BhBh ) 
produce a measure that shows a difference across the two histological types with the x2 
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(green) component showing greater differences.  The M and SD measures showed no 
significance from any of the component images or when applying PCA.   The differences 
in x1-x2, x1-x3, and x3-x2, were also investigated and showed no significance with or 
without PCA (not shown). Examples of related textures are shown in Figure 12. Textures 
that showed significance were generated synthetically for demonstration by filtering 
white-noise with the respective filter kernels. A filter is sensitive to the texture it 
generates (i.e. filter texture reciprocity).  When comparing the raw images in Figure 11 
with the related textures shown in Figure 12, it is not obvious that there are 
distinguishable textural differences between the two histology subtypes.  
 
 
Figure 12: Examples of Laws filters. Laws filters were applied to white-noise fields to 
demonstrate three textures: SS (left), WW (middle), and RR (right). 
 
To assess whether the measures bring additional information to the process, the x2 
results from WW and RR filtering were used in Cox regression. Using this dataset and 
dichotomizing by histology subtype gave HR= 1.77 (0.995, 3.139) showing a baseline 
trend in that those with SC are at elevated hazard. Controlling for WW(x2) [i.e. the WW 
x2 component] with the two tumor types gave HR=1.95, (1.04, 3.65) indicating the WW 
texture measure at this scale complements the tumor categorical variable. Adding RR 
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(x2) with WW(x2) as controlling factors did not influence findings.  Cox regression was 
performed by dichotomizing WW(x2) at its median  distribution value (65.8) which gave 
HR=1.91 (1.05, 3.47), showing (i) patients with an above median WW(x2) measure have 
a significantly   elevated  hazard, and (ii) the x2 measure at the WW scale is related to 
survival. 
 
Because all three of the WW scale measures showed significance, we restricted the 
pixel level PCA analysis to this measure and reduced the three images to one image 
and applied the WW filter which produced little association (p=0.0391) when comparing 
across histology subtypes. Using Cox regression by dichotomizing at the median, which 
gave HR = 0.929 (0.522,1.652).  We then applied PCA at the summary level and 
combined the three standard deviation measures derived from WW which separated the 
two tumor types (p=0.035), but was not better than that provided by WW(x2) in isolation 
(see Table 17). We then combined W(x2), WW(x3) and RR(x2) with PCA, which also 
separated the two groups (p=0.0295), but was not better than provided WW(x2) in 
isolation. 
 
In summary, a measure from the TMA green image filtered with the WW or RR Laws 
two-dimensional filter kernels was related to both histology subtypes and survival. 
 
5.4.2 Tumor-Grade Associations 
The analyses discussed above were repeated on the same dataset to compare the 
groups of patients belonging to the three different categories of tumor-grade (i.e. 
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grades1-3). Raw tumor image examples for each grade are shown in Figure 13. The 
results of SS filtering are shown in Table 17. None of the raw pixel measures (SD, M, or 
spectral component differences) showed significance (not shown) or other filters gave 
significant results (not shown).  In this table for example x1(1,2) indicates a comparison 
using grade 1 samples with grade 2 samples  from the red image.  
 
 
Figure 13: Tumor-grade examples. This shows tumor-grade examples for grade 1 (left), 
grade 2 (middle), and grade 3 (right) tumors. 
 
Table 17: Texture analysis with the SS filter.  This gives the p-values from the T-tests by 
comparing patients with the various grades with the red (x1), green (x2) and blue (x3) 
components separately. For example, x1(1, 3) is comparing grade 1 and 3 in the red 
component. 
Red x1(1, 2) x1(1, 3) x1(2, 3) 
p-value 0.22 0.03 0.06 
    
Green  x2(1, 2) x2(1, 3) x2(2, 3) 
p-value 0.16 0.02 0.08 
    
Blue  x3(1, 2) x3(1, 3) x3(2, 3) 
p-value 0.25 0.02 0.04 
 
As shown in Table 17, most significant differences were found when comparing grade 1 
samples with grade 3 samples in all three components (P<0.05). However, the 
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difference between grade 2 and 3 was significant only in the blue component giving p-
value= 0.04. 
 
Based on the above results, the measurements of the three SS filtered components (red, 
green and blue) were modeled with logistic regression (LR) using a two category grade 
system.  Grade 1 and grade 2 samples were combined to form one composite grade as 
the reference outcome and grade 3 samples formed the other outcome.   The measures 
of x2 (green) and x3 (blue) components were found to be significantly associated with the 
grade: x2 OR = 0.62, (CI: 0.38 0.78) and x3 OR= 0.61, (CI: 0.36 0.88) per SD increase 
(SD=23.6 and SD=12.1 respectively). This indicates that a patient with a decreased 
texture score is more likely in the grade 1-2 group. These results are consistent with the 
findings from the T-test as shown in Table 17. No association was found with survival 
outcomes when stratifying by these two modified grade groups (not shown).  When 
comparing the images shown Figure 14, textural differences are not distinguishable by 
observation.  As above, PCA was not productive.  
 
The texture analysis using grade as the endpoint found measures related to a hybrid 
grading scale.  This suggests the stage 1 grade may be better categorized as a two-
state problem.  It is important to note the most significant grade findings resulted from 
the blue and green images using the SS scale.  In contrast, the most significant tumor-
type findings were derived from the WW and RR scales from the green images.  
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5.5 Brief Image Analysis Summary  
In summary, a method of preparing TMA images for automated processing was 
developed and evaluated. Relationships were established relating various image 
textures to histology, survival, and tumor-grade indicating the system developed here for 
automated TMA analysis is a valid approach.  
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Chapter 6: Discussion 
 
Various aspects of stage I NSCLC were investigated using a diverse dataset with a 
multifaceted analysis. This evaluation included survival analysis and favorable outcomes 
modeling using clinical and pathological variables with accepted epidemiologic 
approaches.  Novel repair protein expression DNA measures were investigated as 
biomarkers for survival. Multivariate models were investigated to determine measures 
related to recurrence. A method was developed to integrate kernel based statistical 
learning methods with accepted epidemiologic practice, essentially fusing the strengths 
of both approaches. A system was developed to analyze tissue microarrays with 
automated image processing methods.  The various methodologies and findings are 
summarized below.   
 
6.1 Baseline Clinical and Pathological Variable Evaluation and Modeling Strategies 
For patients with stage I NSCLC, the favorable outcome modeling showed that younger 
age and female gender were associated with a favorable survival. These findings were 
also observed previously [2, 15, 42].   This analysis demonstrated that the histological 
subtype in combination with gender and recurrence provided the greatest predictive 
value for a subset of patients.  The four category histology-subtypes, tumor-location, and 
smoking status were not significant.  We also found that increasing age was related to 
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the SCC histology subtype, and increasing tumor-grade was related to male gender. The 
work also showed that none of the clinical or pathological factors (described in Chapter 
2) were related to recurrence.  
 
For the favorable outcomes analysis, a method was established of dichotomizing the 
patient population by incident and censored group membership [19], which is a different 
approach than taken by other researchers [22].  This approach may be better suited for 
limited datasets because it does not require discarding data (see Chapter 2). The 
approach can also serve as intermediate step to find variables that may be related to 
survival as evaluated with Cox-regression or Kaplan Meier analysis (see Chapter 2 and 
Chapter 4).    
 
Notwithstanding the dichotomization approach, it could be argued that the LR favorable 
modeling was suboptimal because the time-to-event variable resolution was reduced to 
a coarser dichotomous variable. However for a specific set of variables, the LR output 
provides a different metric (i.e. probability of having a favorable outcome) than that 
provided by Cox regression (i.e. instantaneous relative risk). Moreover, Kaplan-Meier 
analysis provided a population level evaluation and is therefore not suited for individual 
predictions. Thus, the resolution reduction is the price paid for an alternative output. The 
LR modeling (or more generally binary classification) may be more suitable for clinical 
based predictions at the patient level because the output is easily interpretable.  
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The survival analysis (Kaplan Meier and Cox regression) of the standard clinical and 
pathological variables (Chapter 2) clearly showed that younger age, AC histology sub-
type, negative for disease recurrence, and female gender confer longer survival.  
Differences within stage I subgroups were not directly related to survival. However, when 
considering patients with certain clinical and pathological factors with stage IA, their 
survival prospects were better. Younger age patients with both the AC histology subtype 
and Stage IA disease have better survival outcomes. This work showed that tumor-
grade was not a significant variable for influencing these patients’ survival outcome 
when using accepted approaches, which is in contrast with other findings [2] that also 
used accepted approaches.  The increased hazard for SCC patients in comparison with 
AC,  male gender, and increasing age were significantly greater than those found in 
related work [2], which may be due to either population or timeframe differences.  The 
survival findings with adjuvant therapy were consistent with a recent meta-analysis that 
documented an increased hazard ratio for adjuvant chemotherapy in patients with stage 
IA NSCLC [43], although the findings in this dissertation showed only a trend.  
 
The fact that adjuvant chemotherapy did not influence survival in this cohort of patients 
is not surprising. In randomized studies for early stage NSCLC, adjuvant chemotherapy 
improved survival for patients with stage II and IIIA disease [44]. For patients with stage 
IA disease, a meta-analysis demonstrated a hazard ratio of 1.4 with adjuvant 
chemotherapy, suggesting that this group did not benefit. For patients with stage IB 
disease, the available evidence indicates that patients with tumor size greater than 4 cm 
might benefit from cisplatin-based chemotherapy. 
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6.2 Novel Biomarkers 
With the advent of molecular and genomic approaches in cancer research, there has 
been increased interest in the study of protein biomarkers in clinical tumor tissues [45]. 
Genomic instability is a significant attribute of cancer cells that facilitates tumor 
progression [46]. DNA repair capacity has been shown to be a prognostic factor in 
NSCLC patients with resected tumors.  Patients with tumors that showed a high ERCC1 
expression (i.e. a repair mechanism) had a more favorable prognosis and therefore did 
not benefit from adjuvant cisplatin-based chemotherapy [23]. Other proteins involved in 
DNA damage repair mechanisms such as Ku86 and PARP have not been studied to any 
extent in NSCLC. Thus, it was hypothesized that these repair mechanisms may be 
related to survival or recurrence. To the contrary as shown in Chapter 3, PARP and 
Ku86 expression did not provide significant associations with favorable outcome, 
survival, associations with other variables, or recurrence with the exception that Ku86 
expression showed a significant association with male gender. No prognostic 
significance was found for these markers in this study population, perhaps because of 
the retrospective nature of the study.  Nonetheless the observed association between 
Ku86 expression and patient gender can inform testable hypotheses to be evaluated 
using larger sample sizes and an appropriate matched control group in a prospective 
setting. It is notable, agents that modulate PARP and the homologous recombination 
repair are currently in clinical studies. Discovering predictive biomarkers for these agents 
requires a thorough characterization of expression of the target in the tumor tissue and 
other related pathway markers. For this reason, the results of this study are relevant for 
drug development efforts with agents that modulate DNA damage repair pathways. 
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In summary, the novel biomarker analysis resulted in important negative outcome 
experiments. The DNA repair measures were modeled with the clinical and pathological 
factors and no significant relationships with survival were found. Moreover, none of 
these factors or combination of factors provided significant associations with recurrence. 
The prognostic value of recurrence in predicting favorable (or unfavorable) outcome or 
survivability may be limited in general because about 64% of the incident and 92% of 
censored group patients were negative for recurrence (or unknown for the censored 
group). However, positive recurrence is a sure indicator of an unfavorable outcome. A 
better understanding of those factors that can predict recurrence is required.  
 
6.3 Statistical Learning and Epidemiology 
Cox regression, Kaplan-Meier analysis, and logistic regression (LR) are important and 
widely used epidemiologic techniques.  These methods are readily available in many 
software packages and they provide important epidemiologic interpretations. Cox 
regression and LR modeling are parametric and by nature assume a specific output and  
input variable covariate forms. The forms can be changed by user imposition. On the 
other hand, kernel based statistical learning methods assume no specific data form and 
can operate on small datasets with complicated relationships between the covariates 
and output. However, SL approaches do not provide a readily interpretable 
epidemiologic output and they can require more specialized training techniques that are 
often not commercially available. 
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A technique for incorporating SL methods with epidemiologic analyses was developed 
and evaluated in Chapter 4 [19]. The approach used ensemble averaging with bootstrap 
sampling [39] to overcome data limitations. Differential evolution was developed to 
determine the kernel weights.  This is an evolutionary processing technique for global 
optimization problems based on the work by Storn and Price [47].  Age and tumor-grade 
were combined with the modified PNN and were used as inputs to logistic regression 
and survival analysis (i.e. a hybrid approach). This hybrid approach was compared with 
the accepted methods of using these raw clinical variables as inputs.  These findings 
indicate the hybrid approach provided greater Az in the logistic regression modeling and 
greater hazard relationships in the survival analyses than that of the accepted 
approaches using the respective variables. In contrast with the findings discussed in 
Chapter 2, grade was related to survival outcome when combined with age. The internal 
validity of these findings are supported by the cross-validation analysis and the 
simulation methods discussed in the Chapter 4. This approach represents a framework 
that is easily generalized.   
 
The SL output was used as the input into LR model and survival analysis. This approach 
combines the strengths of SL and accepted epidemiologic practice. In this capacity, the 
SL device was operating as frontend preprocessing step for these accepted analysis 
techniques. Processing the SL output with these approaches provides a mechanism for 
converting the SL output into epidemiologic metrics, such as ORs and HRs.    We used a 
relatively simple SL device by converting the PPN classifier [29] to give a patient-score 
to demonstrate the concept with a two-class probability problem. This specific approach 
can be extended to include more than two classes (e.g. death, greater than three, and 
five year survival benchmarks). The PNN applies to multiclass problems, as well, and 
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multinomial logistic regression can address multiple level outcomes.  The PNN classifier 
was converted to provide an output score for each patient, which is a different 
application. For example, the PNN has been used as a classifier in other types of 
survival and medical research [48, 49].  
 
The approach presented in Chapter 4 based on the PNN represents a simplifying step to 
demonstrate the main principles. There are more sophisticated methods that can be 
used within this SL-epidemiologic framework.  More generally, the same hybrid 
approach is applicable for the output of any other type of SL method or decision device, 
such as support vector machines, kernel based partial least squares, or other types of 
neural networks [50-54]. Thus, any combination technique can be used in place of the 
modified PNN shown in the schema in Chapter 4.   
 
Generalizations of the LR model, incorporating kernel based techniques, and neural 
networks into epidemiologic studies represents a diverse field of inquiry. Neural 
networks have been adapted to survival analysis by predicting survival time intervals for 
intraocular melanoma [52].  Earlier research used a PNN and LR modeling to predict 
survival in early stage NSCLC but did not fuse the models [55].  Logistic regression is a 
member of a family of generalized linear models.  Replacing the LR argument with 
various forms of smooth functions has provided benefits in the study of colon-cancer 
[56], heart-disease [57] and infant mortality [58]. Other researchers have incorporated 
univariate kernel density estimations for studying prostate-cancer [59], health disparities 
[60], and nutrient intake [61]. Similarly, univariate kernel density estimations have been 
used to estimate summary measures that were incorporated into LR modeling in fast-
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food consumption studies [62]. Our work differs from this other work in that the PNN (or 
kernel mapping) application makes no assumption concerning the functional relationship 
of the variables under study and we incorporated the measures into LR.  Many of the 
medical uses of neural networks are reviewed elsewhere [63]. 
 
6.4 Image Processing and TMA Data  
Tissue microarrays (TMAs) are emerging as an important research tool. These arrays 
allow for the analysis of DNA, RNA, and protein expression on a large number of clinical 
samples (i.e. tumor samples) simultaneously [64] using laboratory assays such as IHC 
or in-situ hybridization [65]. The use of TMAs in comparison with standard whole tumor 
sections on slides offers several benefits and major savings in terms scientific resources, 
such as use of laboratory reagents, technician effort, pathologist effort etc. Moreover, 
recent research with TMAs has led to advancements in quantifying various biomarkers 
[66].  The cost for these expanded datasets is that the quality of data in the TMA images 
may be degraded compared to conventional pathology slides, as discussed below.  
Similarly, different forms of analysis may be required to extract the information from 
these expanded dataset. The manufactures of the TMA imaging equipment, as well as 
other developers, also provide software for image analyses that is often operator-guided. 
For example, work by Behera et al [67] quantified IHC stained TMAs with an operator-
guided approach (Aperio, Vista, CA) that resulted in associations between tumor-nuclei 
with grade and histology. The novel biomarker analysis presented in Chapter 3 also 
used operator-guidance for the measurements.   As discussed in this review [64] scoring 
methods for TMA images are often subjective, although automated methods are under 
development. For example, recent work in lung carcinoma showed that an automated 
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quantitative scoring system for TMAs was significantly correlated with the pathologist 
scoring [68].     
 
In this dissertation, a different approach was taken to analyze TMA images.  A 
customized method was developed to first preprocess the raw images to allow 
subsequent automated measurements from the entire dataset simultaneously without 
operator imposition or discretion.  The preprocessing is essentially a quality control (QC) 
procedure that requires operator-input.  Various automated image measures were 
evaluated. Significant relationships were found with tumor type, survival, and tumor- 
grade resulting from various Laws filters that capture specific texture characteristics. The 
WW (wave) and RR (ripple) filters showed the strongest relationships with the survival 
when applied to the green component image. This showed that those with increased 
filter-scores were at a significantly elevated hazard. When investigating tumor-grade, the 
SS (spot) filter applied to either the blue or green component images showed a 
significant relationship between grade 3 patients compared with the combined group of 
grade 1 and 2 patients; the blue component image provided the greater associations. 
These findings suggest that grade may be better categorized as either a two-state 
problem or perhaps as a continuous variable instead of three states for stage 1 patients.  
Although grade plays an important role in many tumor types, its prognostic significance 
in lung AC has not been established [69]. This is a significant deficiency because the 
majority of NSCLC patients have AC.  In general, there is higher degree of pathology 
concordance for better differentiated tumors and there are no clear standards for 
describing moderate and poor differentiation for NSCLC among pathologists [70]. These 
texture findings are consistent with the known uncertainty in NSCLC grading. The 
various relationships were found at lower resolution and therefore represent preliminary 
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findings. We hypothesize that stronger relationships will result when analyzing these 
images at higher spatial resolutions.  
 
6.5 Limitations of the Study 
There are several limitations associated with our findings, the most significant of which is 
the retrospective data collection and limited number of patient samples.  This limitation 
resulted in incomplete case ascertainment such that the analytic data samples differed 
between various evaluations.  In the parametric LR modeling, we did not consider 
interaction terms in the favorable outcome analysis to limit over-fitting and the 
presentation length. We were able to construct logistic regression models with increased 
predictive capability by limiting the work to two histology-subtypes, which limits the 
model’s applicability.  The recurrence variable was unknown for many of the censored 
patients, suggesting the related findings are preliminary.  The adjuvant treatment 
findings should also be qualified because the specific treatment type and regimen were 
unknown.   
 
We dichotomized the favorable outcome analysis by censored or incident group 
membership, representing a novel separation methodology [19] that will require further 
evaluation. This approach reduces the uncertainty in the status for those patients that 
did not survive but there are likely patients in the unfavorable group that survived past 
some censored group patients. If we assume that the censored group patients did not 
expire the day after losing study contact, their censored time is a conservative estimate 
(i.e. left-limit) of their overall survival time, indicating that the time separation (mean 
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censored and incident times) between the two groups is greater than that specified by 
the separation of the censored and incident group means. This indicates that 
associations found (ORs or Az) are more likely conservative estimates.   Another 
approach [22]  (that could be considered at the standard approach to dichotomizing 
time-to event data)  is to use a survival time cut-point to dichotomize the patient 
population (i.e. no possibility of overlapping survival time). This approach cannot 
accommodate censored patients on the left side of the cut-point (i.e. censored patients 
are discarded), which is not practical for limited datasets. This approach may create an 
artificial separation when there are many samples near the boundary. In our initial 
analyses (not shown), the standard approach using various survival time cut-points was 
considered, but was not productive with this dataset. The generality of our approach will 
require further evaluation with different datasets.  
 
Although DE is a robust approach, there is no guarantee that it will converge indicating 
that the findings may be less than optimal. The generation termination limits were 
empirically set. Because, we found that letting the process evolve over many 
generations produced weights that were too finely tuned and did not provide 
performance consistency between the training evaluation and the final score 
assessments.  Because the dataset was limited, further evaluation using both simulation 
methods and holdout cross-validation with the patient-score was also provided in 
chapter 4.  The findings from the hybrid modeling will require further evaluations with 
different datasets to show generalization.  In principle to use the system developed in 
Chapter 4 in practice, the sampled patient population should be representative of stage 
1 lung cancer patients in general.   
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While the TMAs play an important role in cancer research and are widely used for 
biomarker studies, they are not routinely used in clinical laboratory testing [65]. One of 
the major concerns associated with TMAs are the small size of the tissue cores and that 
they may not accurately represent the score obtained from a whole section, due to the 
heterogeneous nature of tumor tissue [71, 72]. Hence, multiple cores are usually 
extracted per block, taking the tumor heterogeneity into account. Several studies have 
validated the use of TMA in various tumor sites [73-75] and have demonstrated 
concordance between biomarker scores from TMA and whole sections. The TMA 
technology requires sampling of the tumor tissue at regions containing large amounts of 
cancer cells. These regions of interest are manually selected by visual assessment of 
histology slide images by expert pathologists. Because these methods are new, 
standard automated protocols have not yet been developed to identify the regions of 
interest in the tumor tissue [66]. Hence, our analyses of the TMA data provided here 
were experimental in nature and performed with low spatial resolution data.  Related 
work in whole slide image analysis has been performed by other researchers [76, 77].  
 
6.6 Conclusions 
The work produced several important findings. Baseline survival characteristic were 
estimated for a southeastern contemporary population. This is important because lung 
cancer survival patterns differ regionally and serially. In addition, these measures can 
serve as a baseline to assess whether new measures bring additional information to the 
analysis as in Chapter 3.  The DNA repair expression variables were not related to 
survival, although some associations with SCC and gender in models that included Ku86 
score were found [14]. The worked showed the significance of recurrence limiting 
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survival, which was known [78, 79]. However, none of the clinical or pathological 
variables, novel biomarkers, or combinations of these measures were related to 
recurrence, indicating more work is required to find measured related to recurrence.  A 
platform was established and evaluated to integrate SL techniques with accepted 
epidemiologic practice. In conjunction, a technique was developed as an efficiency step 
to assist in finding variables that may be related to survival via Cox regression or Kaplan 
Meier analysis. A system was developed to analyze TMA images with automated 
measures that first requires operator-input as a QC procedure. Once developing the QC 
system, it takes about 30 minutes to prepare one microarray image for automated 
processing. This system was evaluated with TMA images resulting from standard stains. 
Measures related to survival, tumor-type, and tumor grade were established with this 
system.  
 
Standard statistical methods and experimental methods were developed to analyze the 
clinical and pathological characteristics of this cohort. Several relationships related to 
survival and tumor characteristics were quantified.   These findings may have 
importance to determine optimal therapy and level of aggression required to manage 
stage I NSCLC, specifically. Future work includes (i) investigating novel stains and 
biomarkers with the system developed in Chapter 5 using higher resolution images and 
extending the SL methods developed and evaluated in Chapter 4 to build more general 
models, (ii) applying the methods developed here to our parallel work in lung cancer 
maintenance therapy [7] and the analysis of SCLC [10] as well, and (iii) the continued 
development and expansion of the web-based database in support of our scientific aims 
[20]. The longer-term goal is to develop models for use at the individual prediction level 
for patients with all forms of lung cancer and for understanding lung cancer etiology.   
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